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ABSTRACT OF THE DISSERTATION 
Multiple myeloma (MM) is a debilitating hematologic malignancy of terminally 
differentiated plasma cells in the bone marrow (BM). Advances in therapeutic regimens and the 
use of autologous stem cell transplantation have significantly improved survival rates and quality 
of life in patients. However, the disease remains incurable, with shorter, successive remission 
cycles following relapse. To reduce systemic, off-target toxicity and improve quality of life, there 
is a need for improved stratification of responding patients. Identification of specific, 
noninvasive, imaging biomarkers that correlate to therapeutic efficacy is an attractive strategy 
for stratifying responding patients, since the use of positron emission tomography (PET), 
computed tomography (CT), and magnetic resonance imaging (MRI) is clinically established. 
Here, we have developed a strategy for imaging MM disease pathogenesis and response to 
clinically relevant therapeutics by studying the bidirectional interactions between the BM 
microenvironment and myeloma cells at the cellular, environmental, and anatomical levels. 
Specifically, we have validated imaging markers that identify BM and myeloma-specific 
behaviors through three specific aims: 
The first aim validated the use of the phenylalanine analog 18F-FDOPA for monitoring 
the uptake and efficacy of the DNA alkylating agent melphalan, which is used extensively in 
elderly, non-transplant eligible patients and in relapsed, refractory disease. 18F-FDOPA uptake 
was significantly reduced in melphalan-treated mice with orthotopic myeloma tumors, and was 
concordant with the established 18F-FDG-PET imaging. Immunohistochemistry was used to 
validate 18F-FDOPA uptake results. Importantly, expression of LAT1, which is known to mediate 
18F-FDOPA and melphalan uptake, was visibly increased, although this may be a result of 
increased tumor vascularity. Our results suggest that 18F-FDOPA-PET can provide 
complementary imaging to 18F-FDG-PET for monitoring response to melphalan therapy and 
overall LAT1 expression in MM. 
xii 
 
The second aim assessed the specificity and sensitivity of the peptidomimetic near-
infrared fluorophore LLP2A-Cy5 for imaging the expression of the activated conformation of the 
VLA-4 integrin on the surface of myeloma cells. LLP2A-Cy5 imaging was also used to study 
response to treatment with the proteasome inhibitor bortezomib, which forms the backbone of 
several front-line MM therapy strategies. Uptake of LLP2A-Cy5 was significantly reduced in 
bortezomib-treated mice bearing intramedullary tumors, indicating a reduction in the expression 
of activated VLA-4. These observations are concordant with the known downregulation of 
adhesion-mediated drug resistance and VLA-4 by bortezomib. Our results indicate the viability 
of using LLP2A-Cy5 near-infrared imaging for sensitive, longitudinal assessment of VLA-4 
expression for monitoring bortezomib treatment response. 
Finally, the third aim validated the use of preclinical, multi-parametric MRI for studying 
changes in the BM in a diffuse infiltrative intramedullary tumor model. Longitudinal imaging of 
the BM in the femur and tibia demonstrated significant regional differences in T1-weighted 
contrast uptake and parametric T2 that correlated to changes in viable tumor burden following 
treatment with bortezomib. Hematoxylin and eosin staining (H&E) was used to validate the MRI 
observations. H&E showed complete diffuse infiltration of the BM in untreated animals, while 
bortezomib therapy caused the concentration of tumor burden near the epiphyseal plate of the 
distal femur and proximal tibia. These observations, in combination with MRI results, establish 
the use of preclinical MRI for studying effects of disease progression and therapy response on 
the BM in a longitudinal, noninvasive manner. 
In summary, these studies established a combination of qualitative observations and 
quantitative results in PET, optical, and MRI based strategies. Thus, this project has integrated 
a structured, multi-modal approach for assessing changes in tumor burden and monitoring 
therapy response at varying granular levels within the myeloma/BM interaction spectrum. Future 
studies would adapt this approach into different cell lines and tumor models.
1 
 
Chapter 1: Introduction 
1.1 Overview 
Multiple myeloma (MM) is an incurable, debilitating hematologic malignancy of terminally 
differentiated plasma B-cells in the bone marrow (BM). It is the second most common 
hematologic malignancy and accounts for 15-20% of all hematologic malignancy-related 
mortalities (1,2). In the United States alone, there were over 30,000 estimated new cases and 
over 12,000 deaths in 2018 (3). MM median 5-year survival has improved from 34.6% in 2004 to 
49.6% in 2013 (4,5). This increase in survival is linked to the improvements in diagnosis and the 
availability of autologous stem cell transplantation and combination therapies consisting of 
immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics. However, 
therapy efficacy in the MM clinical population remains variable, especially at late stages in MM 
disease progression. Implementation of personalized stratification strategies is crucial towards 
improving patient quality of life and reducing toxicities and costs associated with ineffective 
therapies. Noninvasive, whole-body imaging has the potential for improving stratification, with 
spatiotemporal localization of therapy response in the MM population. Molecular and structural 
imaging of MM burden and its effects on the BM environment can be studied at progressing 
levels of granularity, ranging from whole tissue to single cell surface biomarker expression. This 
chapter reviews the underlying MM biology, the impact of the BM niche on MM progression, 
current and future treatment strategies, and the increasing use of noninvasive imaging for 
diagnosis and staging. The section concludes with an overview of the three specific aims 
encompassing the efforts towards furthering MM molecular imaging for assessing therapy 




1.2.1 MM is a plasma cell dyscrasia with spatiotemporal heterogeneity 
Multiple myeloma (MM) is a semi-solid plasma cell dyscrasia that develops in bone 
marrow (BM) sites, prior to metastasizing to extramedullary lesions. Traditionally, MM is 
characterized by abnormal serum levels of non-functional monoclonal immunoglobulin-G (IgG; 
M-protein) and the presence of hypercalcemia, renal failures, anemia, and bone fractures 
(CRAB) symptoms. MM is the second most common hematologic malignancy after lymphoma 
and predominantly affects 65+ year-old adults. Figure 1.1 highlights the epidemiology and the 
primary affected populations. 
 
Figure 1.1: Summary of incidence and mortality rates for MM for male and female populations 
in the world. Reprinted from (2). 
Interestingly, myeloma is a spectrum disease, characterized by a transition from 
relatively asymptomatic stages to the symptomatic MM. The asymptomatic stages are primarily 
identified by M-protein levels and their rate of progression to symptomatic MM. The first 
precursor, monoclonal gammopathy of undetermined significance (MGUS), has approximately a 
1 in 100 chance of progression, while the second precursor stage, smoldering myeloma (SM), 
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has a 1 in 10 chance. Genome-wide studies have identified several characteristic genetic 
mutations associated with each stage, although the drivers for the transition from MGUS to 
smoldering myeloma and symptomatic MM are unclear (Figure 1.2) (1,6). 
 
Figure 1.2: Summary of MM progression and genetic diversity. Reprinted from (6). 
As noted in Figure 1.2, MM is characterized by clonal heterogeneity and high inter- and 
intra-lesion genetic diversity. This diversity is driven partly by the underlying B-cell maturation 
process. Immature B-cells are first differentiated from clonal progenitor cells in the 
hematopoietic niches in the BM. In pro- and pre- B-cell stages, cells undergo recombination of 
genes within the variable heavy and light chain loci. This process is known as VDJ 
recombination, due to the involvement of the variable (V), diversity (D), and joining (J) genes, 
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and is central to the generation of antigen recognition. Self-reactive B-cells may undergo 
receptor editing, wherein secondary rearrangement of light chain variable regions generate 
antigen receptors with altered specificity. Failure to complete the maturation phase due to 
continued self-reactivity or other causes may also result in apoptosis via clonal deletion. 
At this stage, immature B-cells leave the BM and are activated by antigen recognition 
and the presence of thymus dependent or independent co-stimulation. Activated B-cells migrate 
to the germinal centers of lymph nodes and undergo somatic hypermutation and class switch 
recombination to develop specificity to the target antigen (Figure 1.3). Both processes are 
mediated by the generation of double strand DNA breaks. These breaks are mostly repaired 
locally, but may be joined to breaks at other sites in the genome. These errors result in aberrant 
chromosomal translocations, which are considered as a genetic hallmark of myeloma. As a 
result of these affinity maturation processes and subsequent maturation to the high affinity 
plasma cell stage, B-cells encounter the potential of significant genetic hits that contribute to 
subclonal heterogeneity. 
 
Figure 1.3: Summary of B cell maturation pathways and terminally differentiated states. NK, 
natural killer; DC, dendritic cell; HSC, hematopoietic stem cell; ELP, early lymphoid progenitor; 
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CLP, common lymphoid progenitor; CSR, class switch recombination; MZB, marginal zone B 
cells. Reprinted from (7). 
Although the etiology of MM is currently unknown, general hallmarks of the disease 
include the upregulation of proliferation and cell survival genes, especially in the 
RAS/MAPK/ERK pathway, immortalization of plasma cells through abnormal plasma cell 
differentiation and resistance to apoptosis via mutations to the P13K/AKT pathways, and the 
upregulation of the NF-κB pathway (6). The primary aberrant chromosomal translocations, 
which have been recognized primary drivers for nearly 50% of all myeloma-related events, are 
the t(4; 14), t(11; 14), t(14; 16), and t(14; 20) (8). Detection of any of these translocations by 
cytogenetic assays is correlated to poor prognosis. Additionally, due to the presence of the 
transitory, asymptomatic MGUS and SM stages, myeloma plasma cells also undergo additional 
mutations and epigenetic changes that contribute to significant spatiotemporal heterogeneity 
within individual nascent BM sites. 
1.2.2 Interaction between myeloma cells and their BM niche is critical to progression 
and survival 
The tumor microenvironment has been increasingly linked to a cancer’s aggressiveness 
and response to therapy (9,10). These observations are especially true for MM, where 
residence in the BM niche protects and promotes the myeloma plasma cell’s immortalization 
and transformation. Due to the outsize role of the BM niche on myeloma pathogenesis, it is 
important to understand the complex cellular and structural characteristics of the BM, and their 
influence on therapeutic response and myeloma disease progression. 
The BM is localized within axial and long bones (11). Bones have external cortical bone, 
which is composed of dense and osseous bone tissue. Cortical bone is organized into 
concentric circles called osteons, with each circular unit made of collagen and calcified 
extracellular matrix (ECM). Nerves, lymphatics, and blood vessels run through the middle of the 
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osteon in the central canal, with orthogonal, branching vessels to supply surrounding tissue. 
Spongy, cancellous bone lines the interior of cortical bone, consisting of lattice-like trabecular 
bone. Sites within trabeculae are primarily linked to hematopoietic activity. Figure 1.4 
summarizes the bone structure and tissue compartments (12). 
1.2.2.1 Adipose Marrow 
The BM is composed, primarily, of adipose, yellow marrow and hematopoietic, red 
marrow. In humans, the adipose marrow constitutes the diaphysis of the long bones. This 
marrow adipose tissue (MAT) can be either constitutive or regulated, and provide endocrine and 
paracrine control of skeletal remodeling and hematopoiesis (12,13). The regulated MAT is 
concentrated in single adipocyte depots in the proximal femur and vertebrae close to 
hematopoietic niches. Regulated MAT expression changes dynamically with external and 
physiological stresses, including cold shock, estrogen levels, and age. By contrast, the 
constitutive MAT is concentrated in large depots and provide the characteristic yellow marrow 
phenotype. Constitutive MAT levels remain relatively stable in response to external drivers, but 
increases primarily with age and follows a spatial gradient from distal tibia and caudal vertebrae 




Figure 1.4: Summary of BM physiology and cellular components.  MSC, mesenchymal stem 
cells; HSC, hematopoietic stem cells; CAR cell, CXCL2 abundant reticular cell. Adapted and 
reprinted from (12). 
The role of MAT in regulating hematopoiesis is controversial in the literature (15). 
Generally, there is an inverse correlation between MAT levels and bone mass in both clinical 
and preclinical studies (16,17), although regions with high constitutive MAT may be better 
protected against bone loss (18). This association is also generally extended to the relationship 
between hematopoietic marrow cellularity and MAT deposits. The inverse relationship may be 
driven by competition for space within the BM cavity between adipocytes and hematopoietic 
cells. This hypothesis is consistent with the observation that implantation of hematopoietic stem 
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cells (HSCs) and adipocyte progenitors result in reductions in overall HSC populations following 
irradiation, at least in part due to expansion of the MAT (19). By contrast, other studies have 
found a positive impact for MAT on hematopoietic activity in the marrow. In caudal vertebrae, for 
instance, secretion of stem cell factor (c-kit) by marrow adipocytes is critical for maintenance of 
hematopoietic cells (20). Additionally, adiponectin secretion is linked to improved HSC activation 
and recovery following irradiation (21). Finally, regeneration of erythroid progenitors and 
granulocytes in leukemia is increased following MAT expansion with peroxisomal proliferator 
activated receptor-γ (PPAR-γ) agonists (22). These studies indicate the complexity and 
heterogeneity in the observed interactions between marrow adipocytes and hematopoietic cells. 
MAT performs an important role in regulating MM through both direct and indirect 
mechanisms. Due to fatty acid lipotoxicity, adipocytes have a well-known inhibitory effect on 
osteoblast proliferation (23). Additionally, secretion of CXCR2-activating chemokines by marrow 
adipocytes may accelerate osteoclast maturation (24). Both of these mechanisms indirectly 
assist in myeloma tumor proliferation by enhancing osteolysis and tumor cell escape from the 
intramedullary space. MAT also produces several tumor-promoting growth factors, including 
interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), and insulin-like growth factor-1 (IGF-1), 
which provide significant endocrine signaling leading to cell migration, resistance, and 
proliferation pathways (25). Activation of the MAPK/ERK and Akt pathways by TNFα, for 
instance, stimulates IL-6 production and autocrine signaling in MM cells in a feedforward loop, 
which enhances cell proliferation and survival (26,27). Additionally, fatty acid secretion by 
marrow adipocytes provides an energy source and serves potentially as an antigen for inducing 
tumor-driving mutations during the MGUS state (27,28). 
As with the complex and contradictory relationship exhibited between MAT and 
hematopoietic tissue, however, there is also significant evidence of inhibitory behavior by the 
MAT on MM. Lipid secretions modulate autophagy signaling, which reduce apoptosis from 
unfolded proteins in either positive or inhibitory roles (25). Furthermore, obesity may provide 
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high-energy lipids and signaling that translates to poor prognosis due to increased drug 
resistance. However, severely obese or morbidly obese patients in one study (n = 1087) were 
found to respond more strongly to melphalan therapy, resulting in improved progression-free 
and overall survival rates relative to normal and overweight patients (29). Furthermore, 
adipokines, such as adiponectin and leptin, also have an impact on MM cell survival. 
Adiponectin is an anti-inflammatory cytokine secreted primarily by adipocytes, but also by 
osteoblasts and BM mesenchymal stem cells (MSCs). Adiponectin expression is decreased in 
obesity, cardiovascular disease, and myeloma (30). Adiponectin inhibits MM proliferation 
through the activation of the protein kinase-A/AMP-activated kinase pathways, resulting in 
increased cell death (31). On the other hand, leptin expression increases autophagy response 
and suppression of apoptosis in melphalan-treated MM cells. Understanding the role of 
individual signaling molecules secreted by adipocytes in the MAT and external adipose tissue 
can assist in developing new therapeutic strategies for MM treatment. 
1.2.2.2 Hematopoietic Marrow 
The hematopoietic (red) marrow primarily constitutes the epiphysis of long bones and 
spinal vertebrae and dominates temporally at early ages, before giving way to increasing 
constitutive MAT. Hematopoietic niches are predominantly localized within trabeculae in the 
perivascular space (32), and are supported by BM stroma, vasculature, and immune cells. 
These niches hold HSCs, which provide the regenerating stem cell basis for erythroid, myeloid, 
and lymphoid progenitors needed to support red and white blood cell production. Although 
HSCs circulate freely in and out of niches, there is evidence suggesting lineage restriction and 
localization of progenitors to specialized niches (32,33). For instance, B-cell progenitors are 
concentrated in CXCL2-expressing osteoblastic niches that are functionally different from 
perivascular niches that primarily maintain HSCs.  
Current literature describes the hematopoietic niches as a complex array of MSC, 
endothelial cells, and hematopoietic progenitors that drive and regulate hematopoiesis (Figure 
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1.4) (12). The presence of MSCs and factors driving their differentiation into the osteoblast 
lineage are linked to HSC expansion and egress from the BM niche (34). Additionally, BM 
macrophages, or osteomacs, are critical for erythroid maturation and proliferation, while also 
facilitating BM homing and quiescence of HSCs (35-37). Indeed, treatment with granulocyte 
colony-stimulating factor was shown to increase differentiation, while reducing osteoblast and 
osteomac populations (37). Finally, a population of CXCL2 abundant reticular cells (CAR cells) 
promote osteoblastogenesis, perivascular space organization, and establishment of the 
microenvironment (38,39). 
Micro-vascularization of the BM niches is regulated by the release of angiogenic factors 
by BM stromal cells (BMSCs), pericytes, and megakaryocytes located within the endosteam. As 
a result, the hematopoietic niches often comprise of a heterogeneous mixture of highly 
vascularized and hypoxic regions. The hypoxic regions generally house the quiescent HSCs 
and progenitors, while more prolific and differentiating cells are localized within the vascularized 
regions (40). The hypoxic microenvironment is maintained by the expression of the hypoxia-
inducible factor-1α (HIF-1α) and its impact on HSC differentiation. HIF-1α is normally degraded 
soon after folding under normoxic conditions by hydroxylating enzymes and the proteasome 
complex (41). Under hypoxic conditions, HIF-1α translocates to the nucleus where it 
upregulates several glycolytic and pentose phosphate pathway related genes (42). As a result 
of this upregulation, oxidative phosphorylation is suppressed, allowing HSCs to tolerate 
oxidative stress and maintain quiescence. These conditions, in combination with the immune 
tolerance induced by large numbers of immune suppressor cells, result in the BM hematopoietic 
niches becoming attractive sites for tumor metastases or generation (43). 
1.2.2.3 Bidirectional communication between MM and BM niches 
Myeloma cell proliferation and survival is greatly facilitated by the conditions in the BM 
niches. The hypoxic environment may play a significant role in the selection of the tumorigenic 
genes and maintenance of the cancer cell stem-like behavior for drug resistance. Additionally, 
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neovascularization is increased through HIF-1α activation of strong angiogenic proteins, 
including the vascular endothelial growth factor-A (VEGF-A) (44). Myeloma cells also generate 
a feed-forward loop that support and accelerate tumor cell proliferation. Production of the 
receptor activator of NF-κb ligand (RANKL) by osteoblasts and tumor cells and subsequent 
stimulation of RANK on pre-osteoblasts results in increases in osteoclast number and activity. 
This, in turn, results in increased myeloma tumor cell proliferation through the release of 
transforming growth factor-β (TGFβ), insulin-like growth factors (IGFs), and calcium following 
bone resorption (Figure 1.5) (45). Additionally, myeloma cells release Dickkopf-1 (DKK-1) in 
phenotypically mature MM cells and soluble Frizzled-related proteins (sFRPs) in plasmablastic 
states to inhibit BMSC differentiation for osteoblastogenesis (46). These proteins are 
antagonists to the Wnt signaling pathway, resulting in the increased production of 
osteoprotegerin and RANKL and subsequent osteoclastogenesis (47). Finally, production of 
chemokines and cytokines, particularly within in the CXCL12-CXCR4 signaling axis, integrins, 
and adhesion molecules by BMSCs and osteoblasts may be linked to improved tumor cell 




Figure 1.5: Summary of the feed-forward loop between tumors and osteolysis, through direct 
(solid arrows) and indirect (dotted arrows) means. (MMPs, matrix metalloproteinases; PTHRP, 
parathyroid hormone-related protein). MMP2s cleave membrane-bound RANKL (blue balls on 
the surface of osteoblasts) or epidermal growth factor-like proteins (red diamonds), resulting in 
an increased osteoclastogenesis via a higher ratio of RANKL to osteoprotegerin. Reprinted from 
(45). 
Interactions with BMSCs provide critical adhesion and drug resistance, through cell 
adhesion mediated drug resistance (CAM-DR) pathways. In the presence of myeloma tumor 
cells, BMSCs produce several growth and survival proteins, including IL-6, IGF-1, CXCL12 (also 
known as stromal cell-derived factor-1 (SDF-1)), VEGF, and RANKL (48). Production of these 
cytokines is primarily driven by the overexpression of the bidirectional very-late integrin-4 (VLA-
4; also known as α4β1) on the surface of the myeloma cells. Expression and activation of VLA-4 
is driven by autocrine signaling via myeloma cell-derived macrophage inflammatory protein-1α 
(MIP-1α) and VLA-4 binding with vascular cell adhesion molecule-1 (VCAM-1) and fibronectin 
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on BMSCs (49). Importantly, VLA-4 is implicated in various myeloma pathogenic behaviors, 
including tumor adhesion, survival, proliferation, and drug resistance (50,51). 
As described in this overview, myeloma pathogenesis is affected significantly by the BM 
niche. Hypoxia, coupled with favorable stromal support and immunosuppressive environment, 
provides an attractive, supportive structure for metastatic cancers, including MM. As a result, 
the development of stronger understanding of myeloma cell interactions at both intercellular and 
environmental levels are critical for improving therapeutic strategies. 
1.2.3 MM treatment strategies induce significant changes in BM-resident cells and 
affect the BM microenvironment 
Therapeutic strategies for MM have advanced significantly in the past two decades, 
resulting in substantial improvements in survival rates and patient quality of life. These 
pharmaceutical agents target a combination of intracellular pathogenic processes in myeloma 
cells and the surrounding environment. This section provides an overview of the literature on 
clinical MM therapies and their intracellular and extracellular effects. 
Clinical stratification and initial treatment plans are predicated on transplant eligibility and 
risk stratification (52). The latter is determined using a combination of factors, including age, 
disease stage, and renal function, with further refinement for overall outcome estimation using 
the cytogenetic type (53). Based on these outcome estimates, a patient is stratified into 
standard, intermediate, and high risk strata. In newly diagnosed transplant-eligible patients, 
autologous stem cell transplantation (ASCT) of the hematopoietic marrow is performed following 
induction with two- or three-drug combination and high dose melphalan conditioning. By 
contrast, elderly, transplant-ineligible patients receive combination therapy followed by single-
agent maintenance. The current treatment algorithm for each risk strata and transplant eligibility 




Figure 1.6: Treatment strategy for risk strata and transplant eligibility in newly diagnosed MM 
patients. (a) Approach in transplant-eligible patients. (B) Approach in elderly, transplant-
ineligible patients. VD, bortezomib-dexamethasone; VCD, bortezomib-cyclophosphamide-
dexamethasone; VMP, bortezomib-melphalan-predinisone; VRd, bortezomib-lenalidomide-
dexamethasone. Reprinted from (52). 
 As noted in Figure 1.6, the majority of combination therapies involve the proteasome 
inhibitor bortezomib. Indeed, the approval of bortezomib for clinical use and subsequent 
combinations with immunomodulatory drugs (IMiDs) is linked to the improvements in overall 
survival seen in the past decade. A decreasing subset of induction combinations use the DNA 
alkylator melphalan as the headlining chemotherapeutic, due to relatively poorer progression-
free survival, overall survival, and higher toxicities. Melphalan-centered combination therapies 
are instead predominantly used in relapsed and multi-drug refractory scenarios. For each of 
these agents, therapeutic efficacy is derived on effecting changes in the targeted myeloma 




Bortezomib (Velcade, Takeda Pharmaceutical, Inc.) is a small molecule, dipeptide 
boronic acid analog. The primary mechanism of action for bortezomib is the reversible binding 
of the 26S proteasome subunit, triggering apoptosis through the unfolded protein response. 
Specifically, bortezomib has high affinity for the β5 subunit, which confers chymotrypsin-like 
functionality. The dipeptide groups form an anti-parallel β sheet conformation via hydrogen 
bonding to conserved amino acid residues in the β5 subunit. The boronic acid moiety forms a 
reversible stable adduct with the catalytic site, resulting in the complete inhibition of the 
chymotryptic subunit and partial inhibition of the tryptic and caspase-like subunits (54). 
The downstream mechanism of action for bortezomib is based on several pathways. 
Initially, the primary mechanism was thought to be through the NF-κB pathway. NF-κB is an 
oncogenic transcription factor that translocates to the nucleus upon proteasomal degradation of 
the inhibiting I-κB (55). Prevention of proteasomal degradation would result in NF-κB remaining 
in its inactive complex. However, several studies showed that this effect was cell dependent, 
since NF-κB was activated through non-proteasomal degradation of I-κB in peripheral blood 
mononuclear cells (56). As a result, it is unlikely that the inhibition of the NF-κB pathway is the 
main mechanism of action. 
Instead, bortezomib induces apoptosis through a combination of intrinsic and extrinsic 
pathways, and the activation of endoplasmic reticulum (ER) stress. In the intrinsic pathway, the 
apoptosis regulator Bax accumulates in the cytosol and translocates to the mitochondria, 
resulting in the release of cytochrome C and subsequent activation of caspase-9 (57). Inhibition 
of proteasomal degradation of the p53 tumor suppressor also results in p53-mediated 
apoptosis. The extrinsic pathway involves the downstream increases in c-Jun N-terminal kinase 
activity and death-inducing receptors Fas and DR5, which enhances caspase-8 activation (58). 
Finally, ER stress is induced by the buildup of misfolded proteins, which triggers apoptotic 
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unfolded protein response and caspase-2 mediated cell death (59). The pathways and their 
components are shown in Figure 1.7. 
Bortezomib therapy also significantly affects the surrounding BM niche. As mentioned in 
Section 1.2.2.3, MM engages supporting BMSCs, osteoclasts, and osteoblasts through a 
vicious feed-forward loop that causes increasing osteolytic activity, neo-angiogenesis, and drug 
resistance. Bortezomib promotes osteoclast apoptosis through the inhibition of p38 mitogen-
activated protein kinase (MAPK), activator protein-1, and NF-κB pathways (60). Osteoblast 
differentiation from osteoblast progenitors and MSCs is also induced through stabilization of β-
catenin, and accumulation of β-catenin and the transcription factor Runx2/Cbfa1 in the nucleus 
(61). Furthermore, bortezomib reduces adhesion to BMSCs through the inhibition of the MAPK 
pathway, which contributes to a reduction in adhesion-mediated drug resistance (62). Finally, 
angiogenesis by BMSCs and other endothelial cells is reduced through down-regulation of 




Figure 1.7: Summary of apoptotic pathways induced by bortezomib-mediated inhibition of the 
catalytic 26S proteasome. Reprinted from (55). 
The success of bortezomib and bortezomib-driven combination therapies in MM clinical 
care has resulted in significant interest in novel, second- and third-generation proteasome 
inhibitors. For instance, the second-generation proteasome inhibitor carfilzomib (Krypolis, Onyx 
Pharmaceuticals) has recently been approved for use in MM clinical care in bortezomib-
refractory disease and frontline treatment (64,65). Carfilzomib is an irreversibly binding 
epoxyketone that also inhibits the chymotryptic β5 subunit (66). The development of these 
agents is needed to overcome the challenges of off-target toxicity and cell line-dependent 
resistance to bortezomib, which is primarily mediated by mutations in the proteasome subunit 
β5 gene and increases in proteasomal capacity (67,68).  
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1.2.3.2 Immunomodulatory drugs (IMiDs) 
BM niches have immunosuppressive environments that provide a favorable area for 
myeloma tumors, especially following the expansion of myeloid derived suppressor cells 
(MDSCs) and regulatory T (Treg) cells. Both MDSCs and Treg levels are increased in the tumor 
microenvironment and in the peripheral blood (69). MDSCs and myeloma cells have a 
bidirectional relationship (70). MDSCs induce myeloma tumor growth through suppression of T-
cell mediated immunity, while myeloma cells promote MDSC differentiation from healthy 
peripheral blood mononuclear cells. Tumor-induced MDSCs may also contribute to tumor-
associated osteolysis due to an increased potential to differentiate into mature, functional 
osteoclasts relative to non-tumor controls (69). 
Tregs are a subset of CD4+ T cells that suppress antigen-presenting cells and effector T 
cells through direct binding or release of IL-10 and TGF-β (69). Increases in Treg levels in the 
tumor microenvironment and peripheral blood are correlated to poor prognosis. However, the 
direct mechanism of myeloma induction of Tregs is not well understood, although in vitro studies 
suggest direct induction in an antigen-presenting cell independent way (71). Regardless, the 
inhibition of excess immunosuppression by MDSCs, Tregs, and other tumor-related immune 
cells is critical for improving outcomes. 
In MM clinical care, this strategy is primarily implemented using immunomodulatory 
drugs (IMiDs), often in combination with a proteasome inhibitor or melphalan, and a 
corticosteroid (e.g., dexamethasone, prednisone). IMiDs currently used for MM are the first-
generation thalidomide and second-generation lenalidomide (Revlimid, Celgene Corporation) 
and pomalidomide (Pomalyst, Celgene Corporation). While the exact mechanism of action is 
unclear, IMiDs induce immunostimulation and MM cytotoxicity through several direct and 
indirect pathways. Specifically, second-generation IMiDs cause myeloma cell apoptosis through 




IMiDs also disrupt the interaction between the myeloma cells and their surrounding 
microenvironment by downregulating adhesion, neo-angiogenesis, and the release of cytokines 
and growth factors (Figure 1.8A) (73). Thalidomide inhibits TNFα, resulting in the 
downregulation of cell surface adhesion molecules, including VLA-4, lymphocyte function-
associated antigen-1 on plasma cells, and VCAM-1 and the intercellular adhesion molecule-1 
(ICAM-1) on BMSCs (74). Thalidomide and the second-generation IMiDs also inhibit other 
inflammatory cytokines to varying degrees, although the contribution of this action towards 
curtailing MM activity is uncertain. Finally, IMiDs display anti-angiogenic behavior, by abrogating 
VEGF and basic fibroblast growth factor (βFGF) production through interference of PI3K/Akt 
pathway in both BMSCs and plasma cells (75,76).  
In addition to disruption of the BM-myeloma environment, all IMiDs augment adaptive 
and innate immune system response to MM to some extent (Figure 1.8B), although there is 
conflicting evidence for mechanisms or the overall in vivo effect. IMiDs, particularly lenalidomide 
and pomalidomide, induce co-stimulation of partially activated CD4+ and CD8+ through 
increased production of IL-2 and interferon-γ (IFNγ) (77). The production of IL-2 also promotes 
natural killer (NK) cell proliferation, and the second-generation IMiDs also enhance antibody-
dependent cellular cytotoxicity and the natural NK cell cytotoxic function (78). In Tregs, 
lenalidomide and pomalidomide reduce expression of the transcription factor FOXP3, and 
subsequently the population and function of the Tregs within the overall T cell population (79). 
Despite these observed in vitro effects, the degree to which IMiDs affect 
immunosuppression, or general immunoparesis, is unknown. In part, this may be due to the use 
of the corticosteroid dexamethasone, which functions as an immunosuppressant. As a result, 
patients responding to combination therapies containing dexamethasone and an IMiD show a 
significant reduction in T and B lymphocytes, and NK cells. Additionally, Treg suppression in 
vitro does not fully translate to clinical results, where response to lenalidomide therapy 
correlated to a relative increase in the Treg population, relative to normal MM patients (73). 
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Furthermore, there is no significant inhibitory effect on the suppressive function of MDSCs by 
either bortezomib or lenalidomide, resulting in increased levels of MDSCs in both BM and 
peripheral blood of MM patients (80). 
 
Figure 1.8: Summary of (A) microenvironment and (B) immune system effects induced by 
IMiDs. APC, antigen-presenting cell; NKT cell, NK cells with T lymphocyte markers and 
functionality; ADCC, antibody-dependent cellular cytotoxicity. Adapted and reprinted from (73). 
Given the complex, environment dependent efficacy of IMiDs and their safety profiles, 
and the importance of modulating and reducing immunoparesis, there is a significant push in 
developing novel cancer immunotherapies, vaccines, and adoptive T cell transfer mechanisms. 
Work in engineering chimeric antigen receptor T cells, immune checkpoint antibodies, and 
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cancer vaccines has shown considerable promise and potential clinical value. However, 
discussion of these technologies is beyond the scope of this review. 
1.2.3.3 Melphalan 
Melphalan (L-phenylalanine mustard) is one of the oldest chemotherapeutic agents still 
used to treat MM. Originally approved in 1962, melphalan is used in combination with 
bortezomib, corticosteroids, and IMiDs for elderly, transplant-ineligible patients and as a high-
dose conditioning regimen prior to ASCT. Due to off-target toxicities and relatively poor overall 
survival rates compared to bortezomib-based therapies, melphalan-centered combinations are 
slowly being phased out in front-line care, although they are used in patients where bortezomib-
based treatment is not feasible (52). 
Melphalan induces cell death by alkylating DNA non-specifically and creating cross-
linked adducts within the DNA. These adducts can result in deletions and strand breaks, 
eventually leading to downstream apoptosis through Bax activation and cytochrome c release 
(81). Melphalan may also contribute to the disruption of BM myeloma microenvironment by 
inhibiting IL-6 production in BMSCs and osteoblasts, thereby reducing MM autocrine signaling 
and recruiting inflammatory cells to the BM niche (82,83). Interestingly, melphalan has also 
been suggested to provide immunomodulatory effects in the BM microenvironment, by recruiting 
CD8+ T cells and reducing Treg and MDSC populations (84). 
1.2.4 Summary 
MM is a highly clonal disease that is significantly influenced by its tumor 
microenvironment. Myeloma cells utilize bidirectional signaling with other cells in the BM milieu, 
including immune cells, BMSCs, osteoblasts, and osteoclasts, resulting in increased myeloma 
proliferation, survival, and drug resistance. Although current therapeutic regimens effect marked 
reductions in adhesion-mediated resistance, immunosuppression, vascularization, and tumor 
burden, MM remains an inherently incurable disease. Indeed, following relapse, each therapy 
cycle is successively shorter, resulting in increasing resistance to treatment regimens (85). 
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Resistance and relapse are driven by clonal evolution and selection of drug resistant cells, and 
adhesion-mediated activation of anti-apoptotic pathways (86). As a result, methods for 
identifying resistant phenotypes early are necessary for reducing off-target toxicities, improving 
patient quality of life, and affecting changes in the treatment strategy for mitigating increases in 
tumor burden. 
1.3 Noninvasive imaging provides spatiotemporal sampling of MM 
staging 
1.3.1 Introduction 
Due to the inevitable relapse and emergence of refractory disease, it is necessary to 
assess response to therapy. As an immunoglobulin secreting disease, the traditional method for 
screening therapy response is by quantifying serum M-protein load, and, latterly, free light-chain 
content with the serum protein electrophoresis (SPEP) and the free light-chain (FLC) assay, 
respectively. Liquid biopsies sampled from BM tissue, typically from long bones or the pelvis, 
provide the percentage of plasma cells in the BM. This information, in combination with imaging 
data such as changes in number of lesions, BM architecture, and tumor metabolic activity, forms 
the basis for monitoring the treatment approach. 
The SPEP assay is a mainstay for diagnosis and staging of MM and its asymptomatic 
precursor states. Using charged, size-dependent diffusion, SPEP assays identify the most 
common serum protein fractions. The presence of monoclonal (M) protein is detected as an 
intense band or spike in the γ-globulin fractions (87). Response to therapy is correlated to M-
protein intensity, since M-protein production is linked to tumor burden. However, SPEP has a 
high detection limit, requiring more than 500-2000 mg/L in serum protein for analysis (88). In 
addition, approximately 15-20% of patients have non-secretory, light-chain, or oligo-secretory 
MM, which prevents the detection of intact immunoglobulins in the sera. Finally, due to the slow 
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clearance rates of IgG antibodies (biological half-life, ~23 days), SPEP is not sensitive to rapid 
changes in tumor burden associated with therapy response (89). 
To ameliorate some of these concerns, serum FLC assay is increasingly used in MM 
staging. In oligo-secretory and light-chain myeloma, M-protein is at low concentrations with 
primarily light chain present in the serum. Serum FLC is more rapidly responsive to changes in 
immunoglobulin production and secretion than standard SPEP or urine protein electrophoresis. 
However, in approximately 3% of initially diagnosed patients and patients that have received 
long-term treatment, there is little to no detectable secretion of intact or light-chain 
immunoglobulin (90). 
Finally, liquid biopsies sampled at the site of myeloma lesions, typically with noninvasive 
imaging guidance, provide changes in total myeloma cells present within the biopsy. However, 
biopsies sample regions within a lesion and are hindered by both the inter- and intra-lesion 
spatial heterogeneity. Because of the clonal and spatial heterogeneity, whole-body noninvasive 
imaging is increasingly used in the diagnosis and staging of MM. Changes in BM tumor 
microenvironment translate to visible, quantifiable changes in imaging parameters. Therefore, 
this section addresses the major imaging technologies used in monitoring treatment response in 
MM. 
1.3.2 Applications of PET/CT in assessing therapy response 
Positron emission tomography (PET) is the workhorse technology for molecular imaging 
and treatment response assessment for clinical cancer care. In particular, [18F]-
fluorodeoxyglucose (FDG) is the primary contrast agent used for imaging due to its versatility 
and applicability for inflammatory diseases. In MM care, FDG-PET is used primarily in staging 
prognosis following treatment, but due to a combination of factors, it has limited sensitivity and 
specificity in intramedullary disease. To assess the role of FDG-PET and its pitfalls in managing 
MM care, it is necessary to understand the mechanism behind contrast generation, FDG uptake 
and retention biology, and promising alternate tracers. 
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1.3.2.1 Principles of image acquisition 
PET is a functional imaging technique that detects and transforms radioactive decay into 
an image. The contrast agents used for PET are unstable, proton-rich nuclei that decay to the 
immediate lower atomic number, while keeping the mass number constant. There are two 
common methods for this decay. The first is via positron emission, where a proton decays to a 
neutron, positron (e+), and neutrino (ν) ((1.1). The other method is by electron capture, where 
the nucleus captures an orbital electron and converts a proton to a neutron, while releasing x-
rays or gamma rays ((1.2). The two methods compete with one another, with positron emission 
dominant in low atomic number (Z) nuclei and electron capture more likely in higher Z nuclei. 
 𝑀𝐴
𝑍 → 𝐷𝐴−1
𝑍 + 𝑒+ + 𝜈 (1.1) 
 𝑀𝐴
𝑍 → 𝐷𝐴−1
𝑍 + 𝜈 (1.2) 
The emitted positron has a very short lifetime. Upon encountering an electron, the 
positron and electron combine and annihilate, resulting in the generation of two 511 kilo-
electronvolt (keV) γ-photons traveling in opposite, collinear directions. This process has several 
advantages that are harnessed for PET image generation. The first is that the generated 
photons have energies that are an order of magnitude higher than those of diagnostic x-rays, 
which reduces risk of attenuation by tissue and enhances external detection. More importantly, 
the collinear nature of the emission is detected at opposite ends within a timing window, 
resulting in coincidences that provide collimation without the need for physical collimators. As a 
result, PET offers highly sensitive imaging that translates to improvements in temporal 
resolution and image quality. 
However, this coincidence detection is affected by unwanted coincidental sources, which 
significantly hamper the signal to noise ratio. These unwanted sources include scattered, 
random, and multiple coincidence events. Scattered events are caused by Compton scattering, 
where high energy radiation is deflected off nuclei in the radiation path, resulting in loss of 
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energy. PET detectors have relatively poor energy resolution, resulting in the acceptance of 
different energies, and an incorrect localization of the annihilation event. In random 
occurrences, two γ-rays generated from different events are detected within the timing window. 
The rate of random coincidences is proportional to the amount of activity and the length of the 
timing window. Finally, multiple coincidences occur with the detection of three or more events 
within the timing window. The different types of coincidences, both true and accidental are 
summarized in Figure 1.9. 
 
Figure 1.9: Summary of the types of possible coincidence events in a PET scanner following 
positron annihilation. Reprinted from (91). 
The spatial resolution in PET is primarily affected by the positron decay itself, due to the 
combination of non-zero positron range and non-collinearity. Non-zero positron range stems 
from the distance traveled by the positron before it is annihilated. This energy is dependent on 
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the emission energy, which is sampled from an exponential probability distribution bounded 
between zero and the maximum endpoint energy. The maximum endpoint energy is dependent 
on the difference in atomic mass between the parent and daughter atoms, as well as the excited 
state gamma emission. As a result, the positron range limits the maximum attainable spatial 
resolution in PET. In addition, the positron often has a non-zero momentum when annihilated, 
resulting in the generation of photons that are not traveling in exactly 180o directions. The effect 
on spatial resolution by non-collinear photons is driven entirely by the distance between 
detectors. As a result, this effect is negligible in small animal PET imaging systems, but 
potentially significant in clinical systems. 
Because of the use of coincidence events and the absence of physical collimation, PET 
possesses higher sensitivity than other imaging technologies. Additionally, scan time is 
minimized, leading to improvements in temporal resolution. The main disadvantage of PET is 
the poor spatial resolution relative to structural imaging modalities and single photon emission 
computed tomography. However, the combination of high sensitivity and temporal resolution 
make PET an attractive functional imaging technology for assessing aspects of metabolism and 
receptor densities. 
1.3.2.2 Mechanisms of FDG contrast generation 
FDG is the most commonly used radiotracer for PET imaging and accounts for over 95% 
of all radioactivity generated for medical imaging in the United States. It is synthesized by 
substituting 18F for the hydroxyl group at the C-2 position in glucose. 18F has a half-life of 109.7 
minutes, and is generated with a cyclotron or linear accelerator. As a glucose analog, FDG 
probes glucose uptake for glycolysis, which is required for sustenance and upregulated in high 
energy tissue, proliferative diseases, and inflammation. Furthermore, glucose is linked to 




Glucose uptake is mediated by glucose transporter (GLUT) types 1, 3, or 4. Following 
uptake, glucose is phosphorylated and converted into glucose-6-phosphate by hexokinase, at 
which point it is either shunted towards glycolysis or nucleotide synthesis through the pentose 
phosphate pathway. The primary end product of glycolysis is pyruvate, which is translocated to 
the mitochondria where it enters the tricarboxylic acid (TCA) cycle and oxidative 
phosphorylation. In non-proliferative cells and normoxic tissue, oxidative phosphorylation is the 
dominant pathway following glycolysis for pyruvate, since it produces the most adenosine 
triphosphate (ATP) per glucose molecule. Thus, glucose and its products are linked to several 
tightly regulated metabolic pathways. 
In cancer cells, however, oxidative phosphorylation is minimized, with the majority 
converted into lactate, as per the Warburg effect hypothesis (92). This observation implies the 
predominance of aerobic glycolysis in cancer cells, which increases glucose accessibility for 
generating precursors for fatty acids, nonessential amino acids, and nucleotides, which are 
critical for rapid growth and division. Thus, to support proliferative growth, cancer cells have 
upregulated GLUT proteins, particularly GLUT1, and hexokinase-2 to mediate glucose uptake 
and conversion to glucose-6-phosphate, respectively. 
The upregulation of these proteins provide the impetus for FDG contrast generation. 
Following uptake, FDG is converted into FDG-6-phosphate, which is unable to progress in later 
glycolytic reactions or in the pentose phosphate pathway. Additionally, the hexokinase forward 
reaction is generally irreversible, except in select tissues including the liver, where the enzyme 
glucose-6-phosphatase convert glucose-6-phosphate back into glucose. Therefore, FDG uptake 
is irreversible and correlates to the exogenous glucose metabolism of the cell. 
The irreversible nature of FDG uptake and the upregulation of aerobic glycolysis in 
tumors makes FDG an attractive contrast agent for imaging active tumors in vivo. Furthermore, 
since tumors remain mostly glucose-avid, apoptosis and reductions in tumor burden correlate to 
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losses in FDG uptake. As a result, FDG-PET is one of the main imaging technologies for 
quantifying treatment response in most cancers. 
In MM, however, FDG-PET is not as reliable as in most proliferative cancers. Indeed, 
FDG-PET has over 95% sensitivity in detecting extramedullary lesions, but approximately 60% 
sensitivity for intramedullary lesions (93). This discrepancy may be due to a combination of 
factors. First, intramedullary lesions are composed of largely hypoproliferative cells, in part due 
to the influence of the BM microenvironment. More importantly, MM tumors have inconsistent 
overexpression of hexokinase-2 and GLUT1, which reduces FDG uptake, even in untreated 
tumors. Additionally, uptake of FDG may be compromised by the presence of significant 
inflammation, since inflammatory cells are highly glucose-avid, thereby resulting in false 
positives. As a result, the most recent International Myeloma Working Group (IMWG) have 
deprioritized FDG-PET for diagnostic imaging for MM, although FDG-PET continues to be used 
for staging therapy response, especially in extramedullary lesions (94). 
1.3.2.3 Alternate tracers 
In recent years, there has been an increase in the development and validation of 
alternate radiotracers to probe other features of the myeloma pathogenesis. These probes are 
specific for overexpressed receptors, transporters, and pathways that are necessary for 
myeloma cell function and pathogenesis. The aim of this development is to provide 
complementary diagnostic information, and potential links to therapy efficacy since MM 
treatment induces significant shifts in BM environmental interaction and expression of critical 
pathways. 
In addition to glucose uptake, there are several metabolic pathways with clinical 
significance in MM. Amino acid transport and fatty acid metabolism are two such pathways. The 
synthesis of nonessential amino acids is a vital strategy for all cancers, especially MM due to 
the continual overproduction of M-protein. Indeed, the system L amino acid transport protein 
family is overexpressed in MM, with high expression of the L-type amino acid transporter-1 
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(LAT1) linked to poor clinical prognosis and survival (95). LAT1 is a sodium-independent 
obligatory exchange transporter that mediates the transport of aromatic and branched amino 
acids. Amino acid uptake from these transporters takes part in intracellular signaling, regulation 
of the TCA cycle, protein synthesis, and several other processes. Thus, PET amino acid probes 
mostly study the uptake of amino acids and, therefore, expression of the amino acid transporter. 
The primary tracers studied for this application are tyrosine, methionine, and phenylalanine 
analogs (96). LAT1 imaging for MM using the phenylalaine analog 3,4-dihydroxy-6-[18F]fluoro-L-
phenylalanine (18F-FDOPA) and its connection to melphalan therapy efficacy will be explored in 
this dissertation. 
Fatty acid metabolism is also upregulated in MM. In particular, exogenous acetate 
uptake is increased, due to its role in the biosynthesis of nucleotides, amino acids, and cell 
membrane components (97). Acetate is ligated with coenzyme-A (CoA) to form Acetyl-CoA, a 
highly versatile molecule with several end products. Acetyl-CoA is a precursor for lipid synthesis 
through fatty acid synthases, which are overexpressed in myeloma cells. Our lab has previously 
demonstrated the utility of 11C-acetate for monitoring response to myeloma therapy (98). 
Pharmacological inhibition of fatty acid synthase activity induces significant toxicity in myeloma 
cells in vitro and in vivo. In patients, 11C-acetate uptake has been correlated to systemic tumor 
burden and provided higher sensitivity for detecting intramedullary diffuse and focal lesions 
compared to FDG-PET (99). 
In addition to imaging intracellular metabolism, expression of surface markers can be 
assessed using PET. For instance, we have demonstrated longitudinal imaging of VLA-4 
expression in both intramedullary and extramedullary lesions in vivo, using a 64Cu-labeled 
peptidomimetic that is highly specific for the activated conformation of VLA-4 (100). VLA-4 
expression is linked to myeloma cell survival, adhesion, and proliferation through bidirectional 
signaling with VCAM-1 and fibronectin on the surface of BMSCs. Crucially, VLA-4 is a key 
mediator of CAM-DR, and may be used for monitoring therapy response. 
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1.3.3 Magnetic resonance imaging is increasingly applied to MM diagnosis and staging 
Magnetic resonance imaging (MRI) is a noninvasive structural imaging method that 
provides strong soft tissue contrast and resolution. The use of MRI in MM care has increased 
significantly over the past decade due to its ability to resolve diffuse and focal intramedullary 
lesions. Due to the complimentary potential of multiple endogenous and exogenous contrast 
mechanisms, MRI is an attractive technology for enhanced detection and quantitative analysis 
of lesion changes following therapy. 
1.3.3.1 Overview of MRI contrast mechanisms 
MRI signal is generated through changes in the magnetic spins of hydrogen molecules 
in a strong magnetic field. Hydrogen spins are oriented in the direction of the axis of the 
magnetic field (B0) induced by the scanner. The exposure of the magnetic moment in the field 
induces angular momentum and precession along the axis of B0 at the Larmor frequency, which 
is dependent on the gyromagnetic ratio and the strength of the magnetic field. Thus, at 
equilibrium, the z-directional component of the spin is aligned with B0, while the x- and y-
directional components are incoherent and average to zero. 
To perturb this equilibrium, radiofrequency (RF) energy is added to the system using 
RF coils. RF pulses cause the magnetic moment to become aligned off-axis. The recovery of 
the moment to equilibrium is the primary source of contrast in an MR scan. There are two 
primary contrast mechanisms. Longitudinal, spin-lattice, relaxation is driven by the recovery of 
the z-directional magnetic moment (Mz). Mz inversion by 180o is followed by recovery towards 
the direction of B0. This process follows an exponential curve, with the characteristic relaxation 
time given by T1 ((1.3). By contrast, transverse, spin-spin, relaxation is driven by the loss of 
coherence in xy-plane. The introduction of a 90o RF pulse induces a non-zero average Mxy 
component, which decays back to zero with magnetic fluctuations and transfer of energy 
between magnetic moments. The characteristic relaxation time for transverse relaxation is given 
by T2 ((1.4). 
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 𝑀𝑧(𝑡) = 𝑀0(1 − exp(−𝑡/𝑇1)) (1.3) 
 𝑀𝑥𝑦(𝑡) = 𝑀0 exp(−𝑡/𝑇2) (1.4) 
Localization of the MR signal to specific voxels for spatial characterization of T1 and T2 
decay is performed using external electromagnets, which generate a gradient field in all 
directions in Cartesian space. Gradient pulses are combined with the RF pulse sequences to 
create a spatial distribution of transverse magnetization that is first structured as 2D/3D Fourier 
space, and then reconstructed into an MR image by taking the inverse Fourier transform. In 
general, most MR images are the magnitude component of the Fourier space. Low- and high- 
frequency components of the Fourier space provide the underlying contrast and edge maps, 
respectively. 
The potential library of MRI experiments result in several types of contrast. The primary 
types are T1- and T2-weighted contrast. In T1-weighted imaging, the combination of generally 
low relaxation time (TR) and echo time (TE) results in the selective enhancement of short T1 
regions relative to long T1 regions. Tissue with large macromolecules show efficient transfer of 
energy from the hydrogen nuclei to enable spins to transition from the high energy to lower 
energy state. As a result, tissue rich with macromolecules, such as adipose tissue, possess 
shortest T1, while dilute regions, including water-rich tumors and cysts, have relatively higher 
T1. Thus, tumors are typically hypointense in non-contrast enhanced T1-weighted imaging. 
Introduction of paramagnetic contrast may be used to generate positive contrast, 
through T1 shortening. The most common paramagnetic contrast agents are gadolinium 
chelates. Gadolinium facilitates energy transfer for hydrogen nuclei by chemical exchange of 
water molecules in the inner coordination shell of the gadolinium molecule (101). Gadolinium 
chelates are preferentially taken up in tumor and inflammation regions due to high perfusion and 




T2-weighted images rely on long TR and TE for the enhancement of relatively high T2 
regions, such as inflamed or diseased tissue. T2 dephasing is driven by the molecular 
environment with dipole-driven non-uniformities in the magnetic field. Regions with high 
macromolecular content have a reduced rate of motion for water molecules, resulting in 
increased dipolar interactions and subsequent field inhomogeneities that translate to shorter T2. 
By contrast, water-rich regions with dilute concentration of macromolecules have rapid rates of 
motion, resulting in brief interactions and a more uniform magnetic environment. As a result, 
tumor and cystic tissue appears hyper-intense relative to surrounding tissue. 
1.3.3.2 Current applications in MM 
Due to its strong soft tissue contrast and spatial resolution, MRI is increasingly used in 
MM diagnosis and staging. IMWG recommendations suggest that the detection of one or more 
focal lesions is a leading indicator for the onset of symptomatic myeloma (94). The primary MR 
methods tested in MM clinical care are non-contrast enhanced T1- and T2-weighted imaging, 
diffusion weighted, and dynamic contrast enhancing sequences. 
 Due to the heterogeneous composition of hematopoietic and adipose marrow in the 
adult human vertebrae, T1-weighted and fat-suppressed T2-weighted imaging in a non-tumor 
bearing case show finely textured hyper-intense and isointense signal in the vertebrae, 
respectively. MM intramedullary lesions display focal lesions, diffuse infiltrations, or variegated 
textures that are detectable by T1-weighted and fat-suppressed T2-weighted MRI (Figure 1.10) 
(102). Several traditional biomarkers, including osteoclast numbers, VEGF expression, and 
plasma cell infiltration, are strongly correlated to the presence of these lesions in T1-weighted 
and fat-suppressed, T2-weighted imaging (103,104). T1-weighted MRI especially showed a high 




Figure 1.10: Representative T1-weighted (left) and fat-suppressed (fs) T2-weighted (right) MRI 
of spinal column in a patient with symptomatic MM. White arrow, focal lesion; red arrowhead, 
diffuse infiltration. Adapted and reprinted from (102). 
Most standard MR protocols in imaging MM minimize the use of gadolinium contrast for 
highlighting tumor burden contrast due to the renal toxicity of these chelates. The Food and 
Drug Administration (FDA) black box warning on gadolinium states a risk of nephrogenic 
systemic fibrosis from gadolinium use in patients with renal insufficiencies. MM patients have a 
high possibility of renal failures from the release of calcium and M-protein into blood, which 
makes gadolinium use a significant challenge in MM. Thus, there is significant research in the 
development of alternate T1 and T2 weighted contrast agents, by utilizing ultra-small 
superparamagnetic iron oxide nanoparticles (<5nm) or novel doped iron oxide nanoparticles 
(105,106). The design and validation of these contrast agents is an active area of research. 
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However, gadolinium contrast is used experimentally in both clinical and preclinical 
studies for dynamic contrast enhanced (DCE) MRI. In DCE MRI, an intravenous bolus of 
gadolinium is tracked using a high temporal resolution gradient echo sequence within a field of 
view. Uptake and retention of the contrast agent is a function of vascular density and perfusion. 
Using kinetic modeling and curve statistics, DCE data can be converted into multi-parametric 
maps for the peak uptake, influx and washout rates, and total uptake (107). In MM, increases in 
peak uptake and influx rate derived from two-compartmental modeling of DCE MR in the pelvis 
of treated patients correlated with plasma cell infiltration and vessel density (108). 
DCE MR can also be combined with diffusion-weighted imaging (DWI). DWI is 
dependent on the differential diffusion rates of macromolecules within a magnetic field to 
generate T2-weighted signal at two or more diffusion-sensitizing gradients. The characteristic 
time of the exponential decay in signal is the apparent diffusion constant (ADC). Voxel-wise 
ADC is dependent on several factors, including cell density and tortuosity. In MM, median ADC 
correlated to BM cellularity and vascular density, while showing statistically significant 
decreases following therapy (109). 
Finally, several small studies have explored the use of voxel-wise magnetic resonance 
spectroscopy (MRS) to assess adipose tissue content and the ratio of adipose to hematopoietic 
marrow. MRS probes the 1D chemical spin composition of a region or voxel and provides a 
snapshot of the composing species in that area. MRS is used extensively in imaging brain 
tissue, particularly gliomas, where the presence of glutamate, choline, and other small molecule 
species correlate to disease progression and stage. In MM, the BM signal is generally 
overwhelmed by water and fatty acids, thus rendering MRS as a blunt tool for assessing 
adipose fractions. As discussed in Section 1.2.2.1, there is conflicting evidence on the role of 
the adipose marrow in regulating and protecting myeloma cells in the hematopoietic marrow. 
However, clinical MRS of spinal and pelvic BM has shown significant increases in lipid fractions 
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in responding patients, suggesting an increase in adipose tissue relative to the hematopoietic 
marrow (110). 
In addition to the technologies presented above, there are several imaging and post-
processing strategies explored in the MM MRI literature. There is a recent explosion in studies 
using quantitative texture metrics in combination with non-linear regression models and 
machine learning approaches. These studies may improve assessments of therapy response by 
harnessing more granular information compared to standard statistics. However, research in 
these fields is relatively nascent and requires larger datasets to reduce overfitting and other 
errors derived from the larger, inhomogeneous MM patient population. 
1.3.4 Near-infrared optical imaging provides high-throughput preclinical functional 
imaging 
As discussed in Section 1.3.2, functional imaging plays an important role in the 
diagnosis, staging, and therapy response monitoring in clinical MM care. The primary modality 
is PET, which combines high sensitivity and temporal resolution for assessment of tissue 
metabolic activity. For preclinical testing and validation of contrast agents and biomarkers, 
however, PET has certain disadvantages. The technology is relatively low throughput, and, due 
to the positron-based contrast generation, cannot provide support the use of multiple contrast 
agents in parallel. Multiplexed biomarkers can be used to identify the spatial distribution of 
corresponding metabolic activities at the tissue and individual cell levels. 
One preclinical alternative is to use optical imaging. Optical imaging is low cost and high-
throughput. Additionally, due to the availability of multiple wavelengths that can be utilized, it 
supports the combination of several imaging probes within the same experiment. Crucially, this 
provides a method for multiplexing contrast agents for identifying the spatial localization of 
target markers within the tissue and cells. 
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Fluorescent optical imaging is primarily hampered by its penetration depth and spatial 
resolution. All tissue contain several endogenous chromophores that minimize penetration of 
excitation and emission light, primarily due to absorbance, while background autofluorescence 
contributes to imaging noise. As a result, near infrared (NIR) fluorophores are used for in vivo 
imaging, due to the presence of a local minimum in the absorption of 700-900nm wavelengths 
by oxygenated and deoxygenated hemoglobin (Figure 1.11) (111). This enhances penetration 
and improves sensitivity. 
 
Figure 1.11: Absorption spectra of common tissue components. Hb, deoxygenated hemoglobin; 
HbO2, oxygenated hemoglobin. Reprinted from (111). 
In MM preclinical research, there is paucity of exogenous NIR fluorophores that are 
targeted to myeloma-specific biomarkers. This is partly due to the limited spatial resolution of 
fluorescent imaging methods. Although the optical window affords increased light penetration, 
tissue turbidity, presence of large macromolecules, and other chromophores cause scattering. 
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As a result, fluorescent images exhibit diffuse signal that is more spatially distributed relative to 
its generating region. Several experimental methods and technologies have attempted to 
reduce the effect of scattering on image generation, including tomographic acquisition, 
structured illumination, and scatter correction using Monte Carlo simulations (112-114). 
However, these methods are often application specific. Most early stage MM is intramedullary, 
which severely restricts the use of fluorescence since dense bone tissue increases scattering. 
Despite the limitations, there is some research in imaging joint inflammation for 
osteoarthritis and bone injury applications (115). For instance, use of a NIR bisphosphonate 
analog in a bone loss model demonstrated specific uptake of the contrast agent in osteonecrotic 
areas, indicating regional specificity for modeling bisphosphonate activity in vivo (116). 
Bisphosphonates are also used in MM, often in combination with chemotherapeutics, for 
promoting bone regrowth following myeloma-induced bone loss (117). Another study imaged 
osteoclast activity with a cathepsin-K specific activatable NIR probe to assess bone degradation 
and resorption (118). These studies show promise for bone-specific in vivo imaging for 
preclinical MM models. Additionally, exogenous fluorophores can be combined with transfection 
models that express luciferase or fluorescent proteins for spatial registration of markers. Optical 
imaging of VLA-4 activity in intramedullary, immunocompetent MM is explored in this 
dissertation.  
1.4 Summary 
Multiple studies have shown the dependence of MM tumors on the surrounding BM 
microenvironment and the role of the bidirectional signaling for influencing disease 
pathogenesis and treatment response. Clinical FDG-PET and MRI are critical for monitoring 
therapy response and changing treatment paradigms to minimize toxicities and improve patient 
quality of life. Both PET and MRI provide indirect metrics on state of disease, although PET 
tracers are designed to assess metabolic activity and receptor densities on the tumor cells. As a 
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result, PET imaging correlates to the intra-tumor and tumor-microenvironment interactions, 
which respond to and affect the therapy response. In preclinical imaging, NIR optical imaging 
can provide PET-like sensitivity and offers parallelized biomarker imaging for identifying whole 
tissue expression that can be localized ex vivo. 
By contrast, MRI provides a macro view on the BM tissue dynamics and its response to 
the MM tumors. Use of DCE and DWI in particular highlight angiogenesis and cell density, while 
standard T1- and T2-weighted imaging responds to changes in types of intramedullary lesions 
following treatment. MM clinical care typically utilizes multiple factors, including changes in total 
uptake and number of lesions in FDG-PET, multi-parametric MRI, and a combination of 
cytogenetic, serum, and site-specific biopsied markers, to derive an assessment for diagnostics, 
staging, and response to therapy. Despite several advances in treatment strategies and early 
identification of non-responders for stratification and personalization of care, MM remains 
incurable, with successive relapse cycles lasting progressively shorter. Thus, there is a need for 
the development and validation of contrast agents and methods for rapidly imaging changes in 
BM structure, intratumoral metabolic activity, and tumor to environment interactions. 
1.5 Specific aims and Dissertation outline 
1.5.1 Specific aims 
Myeloma cells’ interaction with the environment and their intracellular metabolic activity 
profiles drive disease progression and therapy efficacy. We have identified the following aims to 
probe disease behavior at intracellular, myeloma to BM environmental signaling, and 
macroscale BM tissue changes in preclinical intramedullary and extramedullary 
immunocompetent models of MM. 
Aim 1: To validate LAT1 surface expression imaging using FDOPA-PET and develop FDOPA-
PET uptake metrics as a surrogate for melphalan efficacy. 
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Aim 2: To study uptake of the VLA-4 specific optical probe for identifying VLA-4 expression in 
vivo and in response to bortezomib therapy. 
Aim 3: To identify preclinical MRI parameters for longitudinal imaging of diffuse intramedullary 
tumor burden in response to bortezomib therapy. 
1.5.2 Dissertation outline 
The current chapter provides an overview of BM and MM biology, therapy strategies and 
mechanisms, and current imaging paradigms in MM care. 
Imaging of LAT1 surface expression and melphalan therapeutic efficacy is covered in 
Chapter 2. 18F-FDOPA-PET uptake in aggressive extramedullary MM was compared to 
structural tumor burden and LAT1 expression using T2-weighted MRI and 
immunohistochemistry, respectively. 
In Chapter 3, in vivo imaging of the activated form of VLA-4 was used to assess 
response to proteasome inhibitor therapy using bortezomib. Uptake of the peptidomimetic 
optical probe in VLA-4 expressing tumor cells was validated using ex vivo flow cytometry and 
planar fluorescent biodistribution. 
In Chapter 4, the overall effect on BM tissue and tumor burden was assessed 
longitudinally using small animal MRI in diffuse, intramedullary disease following bortezomib 
therapy. Tumor burden and changes in adipose tissue distribution and tissue density were 
validated using hematoxylin and eosin staining of the femur and tibia BM. 
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Chapter 2: Imaging melphalan therapy response in preclinical 
extramedullary myeloma with 18F-FDOPA and 18F-FDG PET 
2.1 Overview 
In this study, 18F-FDOPA uptake in an extramedullary xenograft myeloma lesion was 
studied following melphalan therapy. Melphalan related toxicities and poor efficacy is a primary 
reason for the increasing lack of adoption of the chemotherapeutic agent in front-line MM clinical 
care. However, it is a key component of post-relapse treatment strategies and in elderly, 
transplant ineligible patients that cannot receive bortezomib-based regimens. To identify 
responding and non-responding patients, we proposed to use 18F-FDOPA uptake as a surrogate 
for melphalan efficacy, since uptake of both melphalan and 18F-FDOPA is mediated by the L-
type amino acid transporter-1. Importantly, LAT1 overexpression is linked to poor prognosis in 
myeloma, and it is the primary system L transporter that is upregulated in most cancers. 
Our results showed a significant decrease in 18F-FDOPA uptake that was concordant 
with the established 18F-FDG uptake. Immunohistochemistry showed a visible change in LAT1 
expression, although, interestingly, surface density of LAT1 increased following an early and 
aggressive melphalan therapy regimen. This study suggests that 18F-FDOPA-PET/CT can serve 
as a complementary method to 18F-FDG-PET/CT for imaging melphalan treatment response.  
18F-FDOPA uptake was linked to LAT1 expression and melphalan response, with longitudinal 
imaging suggesting stabilization of LAT1 levels and melphalan tumor cytotoxicity. The material 
covered in this chapter is published in the Journal of Nuclear Medicine (1).  
2.2 Introduction 
One of the main therapies used for treating multiple myeloma (MM) is the small molecule 
alkylating agent melphalan (2-4). However, melphalan efficacy is variable in the clinical 
population, especially in relapsed and refractory MM. It is also implicated in various toxicities 
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including severe mucositis and myelosuppression. Thus, stratification of melphalan-responsive 
patients in the MM patient population is critical for reducing therapy-induced toxicities. 
The L-type amino acid transporter-1 (LAT1) is a key mediator in the uptake and 
intracellular accumulation of melphalan and is correlated to melphalan sensitivity and response 
in MM and other cancers (5-7). LAT1 (SLC7A5) is a member of the system L family of 
transporters and is primarily expressed in fetal liver, bone marrow, placenta, and testes (8,9). It 
is overexpressed in MM and correlated to poor myeloma prognosis and survival (7). LAT1 is a 
heterodimer consisting of a light chain (SLC7A5), which provides the amino acid transporter 
function, and a glycosylated heavy chain subunit (CD98), which provides trafficking and 
membrane localization (10,11). LAT1 is implicated in tumor proliferation pathways, through the 
mammalian target of rapamycin and glutamine/glutamate signaling pathways (12). 
The glucose analog 2-deoxy-2-[18F]-fluorodeoxyglucose (18F-FDG) is currently used for 
positron emission tomography (PET) imaging of myeloma and other cancers for disease staging 
and monitoring therapy response. Clinical trials in patients with MM have correlated the 
suppression of 18F-FDG uptake to improved event-free survival (13). 18F-FDG-PET/CT is useful 
for staging and response monitoring in MM, but the sensitivity for detecting marrow involvement 
by MM is variable, particularly with relatively low marrow burden of disease (14). 18F-FDG 
uptake can be increased in the setting of inflammation after chemotherapy and in the presence 
of exogenous or endogenous marrow stimulation. Thus, there is a need for other PET tracers 
with increased sensitivity and specificity for detecting intramedullary myeloma, particularly for 
low disease burden. Additionally, 18F-FDG uptake and retention is mediated by glucose 
transporter-1 (GLUT1) and hexokinase, which are involved primarily in glycolysis. As a result, 
18F-FDG uptake does not report on LAT1 expression and the melphalan sensitivity of MM 
tumors. 
In this study, we sought an alternative tracer that directly interrogates the functional 
status of LAT1. The amino acid PET tracer 3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (18F-
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FDOPA) is structurally related to melphalan and is primarily transported into cells by LAT1 (15). 
18F-FDOPA-PET is mostly used in imaging gliomas and neuroendocrine tumors in cancer 
patients (16,17). Because LAT1 mediates the intracellular accumulation of both 18F-FDOPA and 
melphalan, we hypothesized that the quantification of 18F-FDOPA uptake in myeloma cells will 
correlate with melphalan therapy response. Using an immunocompetent xenograft model of 
murine myeloma, we demonstrate that 18F-FDOPA could serve as a complementary imaging 
agent to 18F-FDG for MM PET imaging and potentially provide additional stratification of 
responders and non-responders to melphalan therapy. 
2.3 Materials and Methods 
2.3.1 Cell Culture and Reagents 
5TGM1-GFP (5TGM1) (originally a kind gift from Dr. G. Mundy, Vanderbilt University, 
TN, USA; 5TGM1-GFP cells were obtained from Dr. Katherine N. Weilbaecher, Washington 
University, Department of Medicine) were maintained at 106 cells/mL in Iscove’s Modified 
Dulbecco Medium supplemented with 10% v/v fetal bovine serum and 1% 
penicillin/streptomycin (all from Thermo Fisher Scientific, MA, USA). Melphalan (Sigma Aldrich, 
MO, USA) was prepared prior to weekly injections from 5 mg/mL 0.1M HCl EtOH stock. 18F-
FDG and 18F-FDOPA were produced in compliance with current good manufacturing practices 
by the Washington University Cyclotron Facility. 
2.3.2 Tumor Model and Melphalan Therapy 
All animal studies were conducted according to protocols approved by the Washington 
University Animal Studies Committee. C57Bl/6 KaLwRij mice were unilaterally injected 
subcutaneously in the lower flank region with 106 5TGM1 cells. All tumor implantation and 
imaging procedures were conducted under 1-2% v/v isoflurane/100% O2 anesthesia. 
Tumor-bearing mice were separated into two independent studies. The first group 
consisted of two independent cohorts of treated (n=7) and untreated (n=6) mice, with melphalan 
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therapy beginning at 14-18 days after tumor implantation. Imaging was performed at week 4 
(Figure 2.1A). The second group (n=3) consisted of mice treated with melphalan beginning 
week 3 after tumor implantation. Imaging was performed weekly immediately prior to the start of 
the therapy regimen and continued until week 5 (Figure 2.1B). Melphalan therapy was 
administered weekly at 10mg/kg intraperitoneally in saline in each of the studies (18). 
 
Figure 2.1: Timeline for melphalan treated and untreated cohorts. Melphalan was administered 
weekly beginning either (A) week 2, with imaging performed on separate, contiguous days at 
the end of the study, or (B) week 3 post tumor implantation. Longitudinal imaging with MRI, 18F-
FDG, and 18F-FDOPA PET/CT was initialized prior to the start of therapy for the week 3 cohort 
and continued through to week 5 post tumor implantation. 
2.3.3 In vivo Structural and Metabolic Imaging 
Prior to PET/CT imaging, tumor structural volume was assessed by calipers and small 
animal magnetic resonance imaging (MRI). Mice were placed supine within a birdcage 
radiofrequency coil and imaged in 4.7 T (200 MHz) Varian/Agilent small animal scanner (Agilent 
Technologies, CA, USA). Respiration and body temperature were maintained at approximately 
50 breaths/minute and 37 oC, respectively. Transverse T2-weighted contiguous slices were 
collected using a spin echo sequence (repetition time, 1.5s; echo time, 40ms; averages, 2; field 
of view, 2.5 x 2.5 x 1.6 cm3; data matrix 128 x 128 x 16). Region of interest analysis was 
performed using ImageJ (National Institutes of Health, MD, USA).  
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18F-FDG and 18F-FDOPA-PET/CT were performed on separate, contiguous days to 
minimize signal cross-contamination. Prior to radiotracer administration, a whole-body 60kVp 
CT was acquired on each mouse. Mice were injected intravenously with 7.4 MBq dosage of the 
tracer via the lateral tail vein. 60-minute dynamic scans were collected following injection of the 
tracer using Inveon PET/CT or Focus F220 PET imaging systems (all from Siemens Healthcare, 
Erlangen, Germany). 18F-FDG-PET/CT was performed after mice were fasted for 6-8 hours with 
access to water. To standardize imaging, 18F-FDOPA-PET/CT was performed after 18F-FDG-
PET/CT. 18F-FDG and 18F-FDOPA-PET/CT images were reconstructed using iterative 
reconstruction and displayed using Inveon Research Workplace 4.2 (Siemens Healthcare) in 
multi-planar views. 
2.3.4 PET Image Analysis 
Volumetric tumor and control tissue regions of interest were defined using companion 
CT and summed PET. Dynamic time activity curves (TACs) were decay corrected and 
converted to standard uptake values (SUV) prior to analysis. The metabolic tumor volume 
(MTV) (volume of tumor with SUV > 0.42*SUVMax) (19), total lesion avidity (TLA) (Mean SUV in 
the MTV (SUVMean, MTV) * MTV), and total uptake (area under the curve of tracer TAC) were 
calculated for 18F-FDOPA. MTV, total lesion glycolysis (TLG) (SUVMean, MTV * MTV), and total 
uptake were also measured for 18F-FDG. To minimize single voxel noise in SUVMax 
measurements, SUVMax was defined as the mean of the 95% isocontour (20). 
2.3.5 Immunohistochemistry 
Tumor tissue was excised, flash frozen in optimal cutting temperature compound (Tissue 
Tek, CA, USA), and stored at -20 oC. Tyramide amplified immunohistochemistry using Perkin 
Elmer TSA-Cy3 kit (PerkinElmer, Inc., MA, USA) was performed as per manufacturer’s 
protocol(21). Briefly, sections were fixed in 4% v/v paraformaldehyde/phosphate buffered saline. 
Endogenous peroxidase and non-specific binding was blocked with 3% H2O2 and 0.5% TSA 
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blocking reagent, respectively. Sections were incubated separately overnight at 4 oC with 1:50 
dilutions of rabbit polyclonal anti-SLC7A5 (Proteintech Group, Inc., IL, USA), anti-GLUT1 
(Abcam, Cambridge, UK), anti-CD98 (Santa Cruz Biotechnology, Inc., TX, USA), and anti-CD31 
(Novus Biologicals, Littleton, CO, USA). The slides were mounted with Vectashield anti-fade 
mounting medium with DAPI (Vector Laboratories, Inc., CA, USA) after signal amplification with 
1:50 TSA-Cy3. Stained slides were imaged on a Zeiss LSM 880 II Airyscan inverted confocal 
fluorescence microscope (Zeiss, Oberkochen, Germany). Slides were sequentially imaged with 
DAPI (excitation/emission 405/465 nm), GFP (excitation/emission 488/509 nm), and Cy3 
(excitation/emission 561/603 nm) filters. As a negative control, muscle tissue excised from the 
contralateral leg was stained and imaged using the described settings. 
2.3.6 Statistical Analysis 
All statistical analysis was performed using GraphPad Prism 5.0 (GraphPad, CA, USA). 
Statistical significance between TACs was determined using 2-way analysis of variance 
(ANOVA) with repeated measures, while 1-way ANOVA with Bonferroni multiple comparisons 
post-testing and Student’s two-tailed t-test were used for avidity, uptake, and volume 
comparisons between tracers, treatment, and tissue types. Lin’s concordance correlation 
coefficients between 18F-FDOPA and 18F-FDG parameters were calculated using MATLAB 
2014b (Mathworks, Inc., MA, USA). 
2.4 Results 
C57Bl/KaLwRij mice implanted subcutaneously with 5TGM1 congenic unilateral flank 
tumors were evaluated for 18F-FDG and 18F-FDOPA uptake at four weeks post tumor injection 
with 60 min dynamic PET/CT. Structural tumor volume was assessed with T2-weighted non-
contrast enhanced MRI. There was heterogeneous structural tumor volume reduction from 
melphalan therapy within the treatment cohort (9.9 ± 7.7-fold) (Table 2.1; Figure 2.2A-B). 
Correspondingly, metabolic volume representing 18F-FDG and 18F-FDOPA uptake decreased in 
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treated mice relative to untreated mice (Figure 2.3A-B). Decay-corrected dynamic TACs 
derived from the tumor volume of interest for 18F-FDG and 18F-FDOPA showed decreased 
overall uptake across imaging time for treated mice (Figure 2.3C-D). Interestingly, treatment did 
not affect time to steady state in 18F-FDOPA TACs, suggesting that melphalan therapy did not 
impact the overall uptake mechanism and washout kinetics in the tumors. 
Table 2.1: Summary of 18F-FDOPA and 18F-FDG measurements 
  
Treated (n=7) 
(Mean ± SEM) 
Untreated (n=6) 
(Mean ± SEM) 
Untreated : Treated 
(Mean ± SEM) 
Avidity 
TLA 13.07 ± 5.89 603.9 ± 165.9 46.21 ± 24.37 
TLG 44.92 ± 12.05 2329 ± 532.1 51.85 ± 18.27 
MTV (mm3) 
18F-FDOPA 22.16 ± 7.67 636 ± 194.5 28.7 ± 13.22 
18F-FDG 28.81 ± 5.35 416.1 ± 182.5 14.44 ± 6.88 
SUVMax 
18F-FDOPA 0.70 ± 0.13 1.48 ± 0.17 2.11 ± 0.46 
18F-FDG 2.84 ± 0.65 7.03 ± 0.84 2.47 ± 0.64 
Total Uptake 
18F-FDOPA 53.06 ± 8.33 118.9 ± 8.55 2.24 ± 0.39 
18F-FDG 138.8 ± 28.18 483.5 ± 58.98 3.48 ± 0.83 
Structural Tumor Volume 
(mm3) 
78.31 ± 53.6 771.2 ± 291.7 9.85 ± 7.70 
 
 
Figure 2.2: Representative T2-weighted MRI transverse images of (A) untreated, (B) week 2-4 
treated, and (C) treated weeks 3-5 post tumor implantation, at the (left) pre-treatment baseline 
and weeks (middle) 4 and (right) 5. 
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Avidity and uptake of both 18F-FDOPA and 18F-FDG were reduced in the treated tumors. 
There was a larger reduction in 18F-FDOPA MTV (28.7 ± 13.2-fold) than 18F-FDG MTV (14.4 ± 
6.9-fold), although this difference in MTV reduction did not translate to significant correlation 
between MTV and structural tumor volume. Reductions in TLA and TLG were similar in treated 
tumors (Figure 2.4A). Overall 18F-FDG SUVmax was higher in both untreated and treated tumors 
than 18F-FDOPA SUVmax untreated and treated tumors (Figure 2.4B; Table 2.1). 18F-FDOPA 
total uptake and maximal uptake metrics fell within control tissue levels upon melphalan 
treatment, as measured relative to bone marrow and muscle, while 18F-FDG uptake remained 
significantly higher relative to control tissue within the tumor (Figure 2.4C). These results 
suggest that changes in 18F-FDOPA uptake may be more specific to melphalan-mediated 
reduction in tumor size than 18F-FDG for this tumor model. 
 
Figure 2.3: Localization of tumor and average time activity profile in treated and untreated 
5TGM1 tumor-bearing C57Bl/KaLwRij mice imaged with 18F-FDG and 18F-FDOPA PET/CT. 
Representative co-registered PET/CT transverse view of (left) untreated and (right) treated 
tumors in dynamic (A) 18F-FDG and (B) 18F-FDOPA imaging. TACs from (C) 18F-FDG and (D) 
18F-FDOPA are displayed (mean ± SEM at each time point), with statistical significance 




Figure 2.4: Distribution of 18F-FDG and 18F-FDOPA uptake and avidity metrics in treated and 
untreated 5TGM1 tumor-bearing C57Bl/KaLwRij mice. Scatter plots with mean and SEM 
distributions are displayed for (A) TLA (left) and TLG (right), (B) SUVMax, and (C) total uptake for 
18F-FDOPA (left) and 18F-FDG (right). Statistical significance between treated and untreated 
cohorts for TLA and TLG was calculated using the two-tailed Student’s t-test, while 1-way 
ANOVA with the Bonferroni multiple comparison post-test was used to assess statistical 
significance between groups and tissue for SUVMax and total uptake (* p < 0.05, ** p < 0.01, and 
*** p < 0.001). 
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18F-FDOPA measurements were also assessed against 18F-FDG using Lin’s 
concordance correlation coefficients. Avidity and MTV in the treated cohort were moderately 
concordant, while SUVMax and total tracer uptake demonstrated poor agreement (Table 2.2). 
Interestingly, 18F-FDOPA TLA and total uptake were correlated more strongly post therapy to 
18F-FDG, while the concordance of MTV and SUVmax between 18F-FDOPA and 18F-FDG was 
relatively unaffected. The lack of concordance between 18F-FDOPA and 18F-FDG in the SUVMax 
and total uptake is likely linked to the difference in uptake mechanisms, while moderate 
agreement between MTV and avidity indicated similar global effects on metabolism in the 
setting of effective therapy. 
Table 2.2: Summary of Lin's correlation coefficient relative to 18F-FDG-PET/CT parameters 
 Treated (n=7) 
Mean (5% - 95% CI) 
Untreated (n=6) 
Mean (5% - 95% CI) 
Avidity 0.41 (0.04 – 0.68) 0.16 (-0.08 – 0.4) 
MTV 0.64 (-0.01 – 0.91) 0.55 (0.01 – 0.84) 
SUVMax 0.03 (-0.11 – 0.16) 0.03 (-0.03 – 0.09) 
Total Uptake 0.21 (-0.02 – 0.42) 0.02 (-0.02 – 0.06) 
 
We next performed weekly 18F-FDOPA and 18F-FDG-PET/CT and MRI to study the 
effect of therapy on established tumors (Figure 2.1B). T2-weighted MRI indicated minimal 
structural tumor volume reduction throughout the therapy regimen (Figure 2.2C). 18F-FDG 
uptake was significantly reduced in week 1 of therapy, with a return to pretreatment levels 
during week 2 (Figure 2.5A; Figure 2.6A). TLG (1.7 ± 0.4-fold), SUVMax (2.1 ± 0.4-fold), and 
total 18F-FDG uptake (2.1 ± 0.4-fold) also increased by week 2 of therapy, suggesting a rebound 
of glucose-avid tumor cells (Figure 2.6B-D). By contrast, 18F-FDOPA kinetics were unaffected 
by the therapy regimen (Figure 2.5B; Figure 2.6A). There was an increase in TLA (2.4 ± 0.9-
fold) between the pretreatment baseline and week 1, which remained consistent at week 2 (0.8 
± 0.2-fold relative to week 1) (Figure 2.6B). There was no corresponding change in SUVMax or 
total 18F-FDOPA uptake (Figure 2.6C-D). These results suggested that treatment of established 
tumors with melphalan may result in the stabilization of the structural and metabolic tumor 
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volumes. Additionally, the lack of correlation between 18F-FDOPA and 18F-FDG uptake indicated 
that acute changes in glucose metabolism are independent of changes in the transport and 
intracellular metabolism of the amino acid 18F-FDOPA. 
  
Figure 2.5: Representative maximum intensity projections of longitudinal (A) 18F-FDG and (B) 




Figure 2.6: Distribution of 18F-FDOPA and 18F-FDG uptake metrics during longitudinal treatment 
and imaging. (A) TACs for 18F-FDOPA (left) and 18F-FDG (right), with statistical significance 
calculated with 2-way ANOVA with repeated measures and Bonferroni comparisons post-test. 
(B) TLA (left) and TLG (right) were calculated for each week, as were (C) SUVMax and (D) total 
uptake from 18F-FDOPA and 18F-FDG TACs. Time points (weeks 1 and 2) were relative to pre-
treatment baseline (week 3 post tumor implantation). Statistical significance for the individual 
comparisons was calculated using 1-way ANOVA with Tukey post-hoc test (*p<0.05, **p<0.01, 
***p<0.001). 
Immunohistochemistry was performed on tissue from both treatment groups to evaluate 
changes in LAT1 and GLUT1 transporter expression. Changes in LAT1 expression were 
modulated by both tumor size and therapy. Mice in the melphalan-treated established tumor 
cohort (week 3 treatment group) had reduced LAT1 (Figure 2.7C top) surface density relative 
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to the treatment regimen started week 2 post tumor implantation (week 2 treatment group) and 
the untreated tumor (Figure 2.7A-B top). The high LAT1 density in the week 2 treatment group 
relative to the untreated tumors could be attributed to the smaller tumor size and increased 
tumor vascular density. Indeed, LAT1 and GLUT1 expression was generally concentrated near 
blood vessels, as confirmed by CD31 staining (Figure 2.8A-B top). The relative lack of LAT1 
signal in the untreated tumor may be linked to the heterogeneous distribution of viable GFP-
expressing tumor cells within the tumor mass. 
 
Figure 2.7: Immunohistochemistry of LAT1 (top) and GLUT1 (bottom) expression for (A) 
untreated and treated tumors with initialization of melphalan therapy at (B) weeks two and (C) 
three post tumor implantation. Expression for each stain was visualized as a maximum intensity 
projection (63X magnification; 20µm scale bar) separately and as a composite with GFP (green) 




Figure 2.8: Immunohistochemistry of CD31 (top) and CD98 (bottom) for representative (A) 
untreated and (B) treated tumors with initialization of melphalan therapy at week 2 post tumor 
implantation. Expression for each stain was visualized as a maximum intensity projection (63X 
magnification; 20µm scale bar) separately and as a composite with GFP (green) and DAPI 
nuclear stain (blue). 
2.5 Discussion 
18F-FDOPA is an aromatic amino acid PET tracer that is effective for imaging gliomas 
and neuroendocrine tumors (16,17). Dimitrakopoulou-Strauss et al showed that 18F-FDOPA and 
18F-FDG uptake provided complementary detection of metastatic melanoma in pretreated 
patients (22). 18F-FDOPA uptake by cancer cells is thought to be primarily mediated by LAT1, 
making it a promising candidate for imaging LAT1 activity in vivo. Since melphalan uptake is 
also mediated by LAT1, we used 18F-FDOPA-PET as a surrogate reporter of melphalan therapy 
efficacy in a preclinical, immunocompetent MM model. We evaluated 18F-FDOPA and 18F-FDG 
uptake parameters, including TLA, MTV, and SUVMax in vivo in unilateral subcutaneously 
implanted 5TGM1 tumors in C57Bl/KaLwRij mice, which served as a model for extramedullary 
myeloma. Importantly, uptake of 18F-FDOPA correlated strongly to LAT1 surface expression and 
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showed a significant therapy-induced decrease in SUVMax, lesion avidity, and total uptake 
relative to untreated tumor.  
Preclinical 18F-FDOPA-PET/CT showed demonstrably different tumor uptake in the 
untreated and the two therapy groups. Immunohistochemistry of the week 2 treatment group 
suggested that decreasing tumor sizes and increased viable tumor fraction were linked to 
increased LAT1 expression (Figure 2.7A-B top). To further validate changes in expression of 
LAT1, CD98 staining was performed. It should be noted, however, that CD98 also forms 
heterodimers with other amino acid transporters, including members of the LAT family(11). 
Additionally, CD98 expression is implicated in increased vascular density (Figure 2.8A-B 
bottom) (23). The correlation between vascular density and LAT1 expression is corroborated by 
11C-methionine preclinical PET studies of gliomas and brain tumors (24). 18F-FDOPA metrics 
also correlated with melphalan sensitivity, with moderate concordance in MTV to the 18F-FDG-
PET clinical reference standard (Table 2.2). The reduction in 18F-FDOPA uptake indicated the 
sensitivity of 18F-FDOPA-PET/CT to melphalan cytotoxicity. 
There was a larger effect on total uptake and SUVMax for 18F-FDG in response to 
aggressive melphalan therapy (Figure 2.4B-C). The 5TGM1 cell line is highly glucose avid and 
aggressive relative to several other human and murine myeloma cell lines. This avidity, coupled 
with minimal GLUT1 surface density differences in untreated and treated tumors, may explain 
the differences in overall uptake of 18F-FDG relative to 18F-FDOPA in this tumor model. 18F-FDG 
SUVMax and total uptake was also significantly higher in the treated tumor relative to non-tumor 
tissue. This effect may be partially explained by the recruitment of glucose avid macrophages 
and other immune cells to the tumor by therapy-induced inflammation. Nevertheless, 18F-FDG-
PET/CT provided accurate identification of overall response, while 18F-FDOPA-PET/CT 
highlighted melphalan-sensitive tumor populations and showed a greater reduction in MTV in 
the treatment group compared to the untreated tumors than did 18F-FDG. 
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The differences in 18F-FDOPA and 18F-FDG uptake induced by the aggressive therapy 
regimen may be overstated by several factors, including variable tumor viability, immunologic 
response, and the homogeneous expression of LAT1 in the viable tumor volume. To address 
these concerns, we performed longitudinal 18F-FDOPA and 18F-FDG-PET/CT on established 
tumors treated with melphalan (Figure 2.1B). There was no significant difference in 18F-FDOPA 
MTV, SUVMax, or total uptake observed during the imaging period (Figure 2.5B; Figure 2.6). 
There was a 2.4-fold increase in TLA between the baseline and first week of therapy, which 
remained unchanged at the second week (Figure 2.6B). Indeed, immunohistochemistry showed 
that LAT1 expression in this treatment group did not differ qualitatively from the untreated tumor, 
which suggests therapy-induced stabilization of LAT1 expression within the tumor environment 
(Figure 2.7C). By contrast, 18F-FDG SUVMax and total uptake rebounded to pre-treatment levels 
after the first week of therapy, indicating reduction in therapy killing effect by the second week 
and stabilized tumor viability (Figure 2.6C-D). These results suggest that functional imaging 
with 18F-FDOPA and 18F-FDG PET/CT may be linked to tumor viability and melphalan therapy 
response.  
Use of indirect metabolic markers such as lesion avidity and radiotracer uptake have 
been established in the literature as potential parameters sensitive to changes in cancer 
staging. TLA and TLG, while derived from similar SUV data, provided different results from total 
uptake, due to the selective volumetric information contained within the MTV. TLA is a crucial 
semi-quantitative parameter that may provide a surrogate measurement for viable tumor 
fraction. TLG is a more mechanistic measurement that represents the tracer uptake mediated 
by the glucose transport proteins and the subsequent intracellular trapping of 18F-FDG following 
phosphorylation by hexokinases. While phosphorylated 18F-FDG is unable to enter glycolysis 
further downstream, TLG can provide information on the changing GLUT1 mediated metabolism 
during disease progression and following therapeutic intervention. Indeed, McDonald et al have 
shown that 18F-FDG TLG, MTV, SUVMax, and the number of focal lesions strongly correlated to 
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MM stage and progression-free and overall survival rates (25). Similarly, our results highlight the 
discordance in the changes in TLA and TLG in response to melphalan therapy in the 
established tumors. Therefore, 18F-FDG and 18F-FDOPA may provide an assessment of tumor 
response to melphalan during early and late stages, respectively.  
This study was a proof of concept investigation into 18F-FDOPA-PET imaging of 
myeloma and the correlation between 18F-FDOPA to melphalan therapeutic efficacy in an 
extramedullary myeloma tumor model. There are several promising results from this study, 
including the correlation between 18F-FDOPA and 18F-FDG uptake with tumor viability and early 
response to melphalan therapy, respectively. Imaging in other human and murine myeloma cell 
lines and animal models with different LAT1 expression and melphalan sensitivity would provide 
additional corroboration for the trends seen within these data. Efflux transporters are 
predominantly linked to melphalan resistance in in vitro studies of melphalan-resistant myeloma 
cell lines (26). Therefore, determining the expression of efflux transporters at various time-points 
during melphalan therapy would also provide important information about treatment-mediated 
transient changes in influx and efflux transporters. Finally, further investigation into 18F-FDOPA 
uptake and washout mechanisms with metabolite fate analyses and competitive inhibition of 18F-
FDOPA intracellular uptake can provide the means for developing strong predictive models of 
melphalan sensitivity with 18F-FDOPA-PET/CT. 
2.6 Conclusion 
This study represents, to date, one of the first investigations linking amino acid-based 
imaging in MM to therapy response, via the correlation of 18F-FDOPA-PET/CT to melphalan 
sensitivity and LAT1 expression. 18F-FDOPA-PET/CT provided viable and complementary 
imaging of MM and melphalan therapy efficacy in this tumor model. Finally, uptake of 18F-FDG 
and 18F-FDOPA in established tumors were discordant early after treatment initiation, indicating 
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the tracers’ independent mechanisms and their individual applications for assessing response to 
different stages of melphalan therapy. 
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Chapter 3: Near-infrared imaging of VLA-4 expression for 
monitoring bortezomib efficacy in preclinical MM 
3.1 Overview 
In this study, the uptake of the near-infrared contrast agent LLP2A-Cy5 was correlated to 
bortezomib therapy response in an intramedullary MM tumor model. Bortezomib reduces 
myeloma cell adhesion to the bone marrow stroma, via the downregulation of the very-late 
antigen-4 (VLA-4) integrin. VLA-4 is a bidirectional heterodimeric integrin receptor that is 
overexpressed in its active conformation on myeloma cells and is implicated in several MM 
pathogenic pathways. We have previously demonstrated VLA-4 overexpression as a promising 
imaging biomarker for monitoring MM disease progression using a high affinity peptidomimetic 
ligand, LLP2A, conjugated to a nuclear contrast agent. Here, we proposed to use uptake of the 
near-infrared fluorescent analog LLP2A-Cy5 for imaging activated VLA-4 overexpression in 
response to bortezomib therapy in syngeneic, intramedullary MM. 
Our results showed significant decrease in LLP2A-Cy5 uptake in the tumor-bearing 
hematopoietic tissue following bortezomib therapy. Flow cytometry and ex vivo tissue 
biodistribution identified reduction in LLP2A-Cy5+ populations across most tissue, indicating the 
anti-inflammatory behavior of bortezomib. This study suggests that LLP2A-Cy5 optical imaging 
can provide an economical and high-throughput alternative to nuclear imaging for imaging 
activated VLA-4 expression and bortezomib therapy response. The material in this chapter is 
part of a prepared manuscript submission to the journal Blood. 
3.2 Introduction 
In multiple myeloma (MM) clinical care, the proteasome inhibitor bortezomib is a key 
therapeutic agent in front-line regimens. Bortezomib therapy modulates bone marrow (BM) 
remodeling by inhibiting the myeloma cells’ interactions with the BM microenvironment. One of 
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the main molecules affected by this interruption is the very-late antigen-4 (VLA-4; α4β1 integrin, 
also known as CD49d/CD29). VLA-4 is a bidirectional integrin receptor overexpressed on 
myeloma cells in the high affinity activated conformation and is strongly implicated in key 
signaling pathways of disease pathogenesis, including cell proliferation, trafficking, and 
adhesion-mediated drug resistance (1,2). The activated form of VLA-4 binds to fibronectin and 
the vascular cell adhesion marker-1 expressed on the surface of BM stromal cells, resulting in 
increased cell adhesion and survival within the BM niche (2,3). Bortezomib inhibits several 
oncogenic pathways, including NF-κB and MAPK cascades, resulting in increased osteoclast 
apoptosis and the downregulation of several inflammatory and angiogenesic cytokines and 
factors (4-6). Bortezomib abrogates BM adhesion by downregulating production of the α4 
subunit in the VLA-4 heterodimer (1). Thus, bortezomib efficacy may be linked to VLA-4 
expression in myeloma cells. 
We have previously demonstrated the affinity of the peptidomimetic ligand LLP2A for the 
activated conformation of VLA-4 in preclinical extramedullary and intramedullary MM (7-9). In 
particular, VLA-4 overexpression was used to monitor MM disease progression in the BM. To 
study in vivo and ex vivo overexpression of VLA-4 in an economical and high-throughput 
manner, we developed a near-infrared (NIR) fluorescent imaging agent by conjugating LLP2A to 
the NIR cyanine dye Cy5 (9). Melanin, hemoglobin, and other endogenous chromophores have 
reduced absorption and autofluorescence in the NIR window (650-900nm), resulting in improved 
depth penetration (10). Here, we have demonstrated LLP2A-Cy5 as a surrogate for activated 
VLA-4 overexpression in syngeneic, intramedullary MM tumors in an immunocompetent mouse 




3.3 Materials and Methods 
3.3.1 Cell culture and reagents 
5TGM1-GFP cells (5TGM1; kind gift from Dr. K. N. Weilbaecher, Washington University, 
Department of Medicine) were maintained at 106 cells/mL in Iscove’s Modified Dulbecco 
Medium supplemented with 10% v/v fetal bovine serum and 1% penicillin/streptomycin (all from 
Thermo Fisher Scientific, MA, USA). Bortezomib (Sigma Aldrich, MO, USA) doses were 
prepared prior to each therapy injection. LLP2A-PEG4-Cy5 (LLP2A-Cy5) and scrambled 
LLP2A-PEG4-Cy5 (scLLP2A-Cy5) were synthesized as previously described (9). 
3.3.2 In vitro LLP2A-Cy5 uptake and specificity 
5TGM1 cells were plated on 35mm glass bottom MatTek dishes pre-coated with poly-D-
lysine (glass no. 1.5; MatTek Corporation, MA) at 105 cells/cm2, and allowed to attach for 1 h at 
37oC. Cells were incubated with 1 µM of the Cy5-labelled probes at 4oC for 15 min, and at 37oC 
for 2.5 h to assess cell surface binding specificity and cellular internalization, respectively. 10 
µg/L Hoechst 34580 (Invitrogen, CA) was added for the last 15 min of incubation to counterstain 
cell nuclei. Fluorescence confocal microscopy was performed on a Nikon A1Rsi confocal 
microscope (Nikon Corporation, Tokyo, Japan) with 60X and 100X oil immersion objectives 
using excitation-emission at 405-450/40 nm (Hoechst 34580), 488-530/20 nm (GFP), and 640-
660/20 nm (Cy5). 
3.3.3 Saturation binding assay 
Selective affinity was determined with fluorescence activated cell sorting (FACS). 
1.5x105 5TGM1-GFP cells were incubated with varying concentrations of LLP2A-Cy5, with or 
without 100nM BIO5192 (Tocris Bioscience, Bristol, United Kingdom), which was used to 
assess nonspecific binding. BIO5192 is a highly specific inhibitor for activated VLA-4 (11). 
Samples were analyzed on a Beckman Coulter Gallios flow cytometer and data were analyzed 
using FlowJo software (TreeStar, Ashland, OR). Total and nonspecific binding coefficients 
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(dissociation constant (Kd) and receptor density (Bmax)) were calculated by fitting mean 
fluorescence intensity (MFI) versus LLP2A-Cy5 concentration using Prism 5.0 (GraphPad 
Software, Inc., CA). 
3.3.4 Tumor model and bortezomib therapy 
All animal studies were conducted according to protocols approved by the Washington 
University Institutional Animal Care and Use Committee. Mice were anesthetized under 2% v/v 
isoflurane/100% O2 prior to tumor implantation. Female 4-8 week old C57Bl/KaLwRij mice were 
injected intravenously with 106 5TGM1 cells, via the lateral tail vein. 
Tumor-bearing animals were divided into untreated (n=5) and treated (n=3) groups. 
Bortezomib therapy was administered intraperitoneally at 1 mg/kg twice a week beginning on 
day 14 post tumor implantation (12). Untreated animals received vehicle control on the same 
schedule. 
3.3.5 In vivo NIR imaging 
Prior to imaging, hair was removed by gentle clipping and depilatory cream to improve 
light transmission. Mice were imaged before and after 18-24 h after intravenous injection of 100 
µL of 25 µM LLP2A-Cy5 in 5% v/v DMSO/H2O using the Optix MX3 time-domain diffuse optical 
imaging system (Advanced Research Technologies, Montreal, Canada) as previously described 
(13). The images were background subtracted to reduce the effects of autofluorescence. 
3.3.6 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7.0 (GraphPad, CA, USA). 
One-way analysis of variance (ANOVA) with Sidak multiple comparisons test was used to 
assess statistical significance between multiple groups, while the Student’s two-tailed t-test was 





The specificity and binding affinity of LLP2A-Cy5 for activated VLA-4 expression on cells 
was tested in vitro in 5TGM1 cells. 5TGM1 cells were first incubated with LLP2A-Cy5 at 4oC to 
reduce non-specific uptake and binding (Figure 3.1A). Cell surface fluorescence was 
significantly reduced when 5TGM1 cells were incubated with the scrambled peptidomimetic 
(5.86 ± 2.25-fold) and 100-fold excess unlabeled LLP2A blocking (5.01 ± 2.04-fold) (Figure 
3.1B, C; Figure 3.2A). Incubation at 37oC for 2.5 h did not result in an increase in intracellular 
uptake, with predominantly cell surface signal (Figure 1D). The binding specificity was further 
corroborated using saturation binding, resulting in Kd of 117.7 ± 8.69 nM (Figure 3.2B). Minimal 
nonspecific binding (NS, 0.01 ± 0.003) was observed in the presence of BIO5192. These results 




Figure 3.1: Representative confocal fluorescent images of LLP2A-Cy5 binding in 5TGM1 cells. 
(A) 1 µM LLP2A-Cy5, (B) 1 µM scLLP2A-Cy5, and (C) 1 µM LLP2A-Cy5 in presence of 100 µM 
unlabeled LLP2A, were incubated with 5TGM1-GFP cells at 4oC for 15 min. (D) 5TGM1 cells 
were incubated with 1 µM LLP2A-Cy5 at 37oC for 2.5 h. A-C, 60X magnification, scale bar, 15 




Figure 3.2: LLP2A-Cy5 uptake in 5TGM1 cells in vitro. (A) Total uptake in cells at 4oC (15 min 
incubation). Integrated density is the product of the region of interest area and mean intensity 
value. (B) Saturation binding of LLP2A-Cy5 in 5TGM1 cells. Statistical significance was 
assessed using 1-way ANOVA with Tukey multiple comparisons test (***p<0.001). 
Next, LLP2A-Cy5 was injected intravenously into end-stage untreated (week 4 post 
implantation) and bortezomib-treated (week 6 post implantation) mice to assess VLA-4 activity 
in response to bortezomib therapy. Imaging was performed 18-24 h after injection of the 
contrast agent. In vivo GFP expression was similar in both groups, although LLP2A-Cy5 signal 
was approximately 5-fold higher in the treated mice (Figure 3.3A, B). LLP2A-Cy5 signal in the 
treated animals was reduced in the pelvis and lower spine, and was primarily concentrated in 
the upper vertebrae and other tissue. In the untreated animals, the spatial distribution of LLP2A-




Figure 3.3: Representative 18-24 h fluorescence signal in C57Bl/KaLwRij mice bearing diffuse, 
intramedullary 5TGM1 tumors. (A) Untreated, week 4 post tumor implantation. (B) Bortezomib 
treated, week 6 post implantation. (Left) GFP, (Middle) Cy5, (Right) Overlay of GFP and Cy5 
signal. Scale bar, 10mm. 
Ex vivo fluorescent biodistribution confirmed that maximal LLP2A-Cy5 uptake was seen 
in the BM and spleen. There was statistically significant reduction in LLP2A-Cy5 fluorescence in 
the end-stage treated BM relative to the untreated tissue (6.34 ± 4.48-fold; Figure 3.4A). 
Indeed, tissue-to-muscle ratios for each of the extracted organs, including BM (1.11 ± 0.55) 
were within 1.26 ± 0.45, indicating minimal uptake of the contrast agent following bortezomib 
therapy. Additionally, GFP signal, which is an indicator for tissue-specific, viable tumor burden, 
decreased significantly in both spleen (3.42 ± 2.0-fold) and BM (9.78 ± 6.28-fold) (Figure 3.4B). 
These data contradict in vivo fluorescence imaging results, which seemed to suggest an 




Figure 3.4: Ex vivo fluorescence biodistribution in end-stage treated and untreated mice. 
Background subtracted fluorescence intensity in each tissue was normalized by the mean 
muscle intensity, and presented as Tissue to Muscle ratios. (A) LLP2A-Cy5 biodistribution. (B) 
GFP biodistribution. Statistical significance was assessed using 2-way ANOVA with Sidak 
multiple comparisons test (*p<0.05). 
 
Figure 3.5: FACS of treated and untreated BM in the femur and tibia. The cell population is the 
percentage of GFP+ and LLP2A-CY5+GFP+ cells within all cells in the BM. Statistical 
significance was assessed using the Student's two-tailed t-test within each gated group 
(**p<0.01, ns, not significant). 
Finally, tumor burden and LLP2A-Cy5+ populations were quantified in both 
hematopoietic organs with FACS. There was no significant change in tumor burden in either BM 
or spleen following treatment (Figure 3.5). By contrast, the activated VLA-4+ cell population 
within the BM was significantly reduced following bortezomib therapy (3.21 ± 1.55-fold). 
Consistent with the fluorescence intensity biodistribution, spleen tumor burden was low, and as 
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a result, remained relatively similar in the treated group compared to the untreated animals 
(1.05 ± 0.96-fold reduction). These data indicate that BM uptake of LLP2A-Cy5 and activated 
VLA-4 expression changes following therapy response with bortezomib. 
3.5 Discussion 
LLP2A-Cy5 is a highly specific peptidomimetic ligand conjugated to a NIR fluorescent 
contrast agent (7,9). It is targeted to the activated conformation of the VLA-4 heterodimer, which 
is overexpressed on the surface of myeloma cells. Overexpression of VLA-4 is linked to 
increased drug resistance in MM, due to its participation in cell adhesion-mediated drug 
resistance pathways (2). In hematologic malignancies, studies have shown conflicting effects of 
VLA-4 expression on prognosis. In acute myeloid leukemia, for instance, overexpression of 
VLA-4 on tumor cells is correlated to better prognosis and low to intermediate disease stage 
(14). In MM, there is some evidence that VLA-4 expression is linked to reductions in overall 
survival and poor response to therapy (15). To further assess the role of VLA-4 in mediating 
therapy response in MM, we studied the uptake of LLP2A-Cy5 in a diffuse, intramedullary MM 
model using the immunocompetent C57Bl/KaLwRij strain. 
We have previously demonstrated that LLP2A conjugated radiotracers have nanomolar 
binding affinities to activated VLA-4 expression on 5TGM1 cells (16). To ascertain the specificity 
of the optical LLP2A conjugate, saturation binding and confocal imaging of LLP2A-Cy5 
incubation with 5TGM1 cells was performed. Non-specific binding was minimal, as 
demonstrated by co-incubation with the VLA-4 inhibitor BIO5192, excess unlabeled LLP2A 
blocking, and a scrambled, non-specific version of LLP2A-Cy5. Furthermore, the dissociation 
constant (Kd) for LLP2A-Cy5 was in the nanomolar range, and within two orders of magnitude of 
the nuclear conjugate. This difference in Kd is likely due to the sensitivity of the PET radiotracer, 
since the PET tracer is unaffected by noise driven by the confluence of optical absorption, 
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scattering, and autofluorescence. Nevertheless, these results demonstrated the specificity of the 
optical LLP2A conjugate for activated VLA-4 expression on myeloma cells. 
Confocal binding specificity experiments were first run at 4oC to minimize non-specific 
uptake and pinocytosis. Thus, fluorescence signal was concentrated at the cell surface with little 
to no internalization. Interestingly, however, when cells were incubated with LLP2A-Cy5 at 
physiologic temperature (37oC) for 2.5 h, cell internalization remained minimal. Fluorescence 
signal was predominantly localized at the cell surface. VLA-4 has a longer cell surface exposure 
relative to other integrins, which suggests that the fluorophore remains trapped at the cell 
surface due to constant integrin recycling (17). This behavior suggests an antagonist 
mechanism for LLP2A-Cy5, since ligand-based activation of integrins results in endocytosis and 
ligand uptake into the endosomes prior to integrin recycling (18).  
Next, LLP2A-Cy5 uptake was used to study VLA-4 expression following bortezomib 
therapy. Bortezomib is known to inhibit VLA-4 expression and downstream adhesion-mediated 
resistance. As a result, we expected reduction in LLP2A-Cy5 uptake following treatment in our 
tumor model. Biodistribution and flow cytometry of the hematopoietic organs corroborated this 
expectation, although, interestingly, there was a similar, though not significant, decrease in 
LLP2A-Cy5 uptake in other tissue, especially muscle and the clearance organs. Bortezomib has 
been shown to have anti-inflammatory properties, with reductions in several inflammatory 
cytokines observed in arthritic models (19). Thus, bortezomib-induced reduction in general 
inflammation and MM-expressed VLA-4 may result in the overall depression in LLP2A-Cy5 
uptake and subsequent rapid clearance from tissue within 24 hrs. 
The decrease in LLP2A-Cy5 uptake in the tumor-bearing organs correlated to tumor 
burden reduction, as measured by flow cytometry. However, in vivo imaging of LLP2A-Cy5 and 
GFP expression contradicted ex vivo data, with an increase in LLP2A-Cy5 signal in the end-
stage, treated cohort. This increase was statistically insignificant, but it suggests the need for 
additional longitudinal experiments. To assess the change in VLA-4 expression noninvasively in 
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response to therapy, LLP2A-Cy5 imaging could be performed weekly, prior to treatment. This 
imaging strategy would also provide necessary normalization and adequate baseline 
comparison for the in vivo fluorescent signal. 
3.6 Conclusion 
In conclusion, our study has demonstrated the comparable viability of LLP2A-Cy5 in vivo 
and in vitro to previously studied nuclear LLP2A tracers. LLP2A-Cy5 showed selective VLA-4 
binding in tumor tissue, with minimal nonspecific uptake in vitro. Additionally, we present the 
utility of LLP2A-Cy5 for tracking activated VLA-4 expression noninvasively in response to 
bortezomib therapy. Future work would include longitudinal observation of LLP2A-Cy5 uptake, 
testing in alternate myeloma cell lines with different VLA-4 expression profiles, and modeling 
bortezomib sensitivity in VLA-4 negative or knockout cell lines. These studies would improve 
understanding of VLA-4-driven stratification of proteasome inhibitor therapy response. 
3.7 References 
1. Noborio-Hatano K, Kikuchi J, Takatoku M, et al. Bortezomib overcomes cell-adhesion-
mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. 
Oncogene. 2009;28:231-242. 
 
2. Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T. Vicious cycle between myeloma cell 
binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage 
inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab. 2009;27:16-23. 
 
3. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human 
myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. 
Blood. 1993;82:3712-3720. 
 
4. von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. 
Leukemia. 2007;21:2025. 
 
5. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits 
growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. 




6. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib Mediates Antiangiogenesis in 
Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. Cancer Res. 2006;66:184-
191. 
 
7. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies 
high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. Nat Chem Biol. 
2006;2:381-389. 
 
8. Soodgupta D, Hurchla MA, Jiang M, et al. Very late antigen-4 (alpha(4)beta(1) Integrin) 
targeted PET imaging of multiple myeloma. PLoS One. 2013;8:e55841. 
 
9. Soodgupta D, Zhou H, Beaino W, et al. Ex Vivo and In Vivo Evaluation of 
Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. J Nucl Med. 
2016;57:640-645. 
 
10. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol. 2001;19:316-317. 
 
11. Ramirez P, Rettig MP, Uy GL, et al. BIO5192, a small molecule inhibitor of VLA-4, 
mobilizes hematopoietic stem and progenitor cells. Blood. 2009;114:1340-1343. 
 
12. Hurchla M, Garcia-Gomez A, Hornick M, et al. The epoxyketone-based proteasome 
inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic 
activity in addition to anti-myeloma effects. Leukemia. 2013;27:430-440. 
 
13. Hathi D, Zhou H, Bollerman-Nowlis A, Shokeen M, Akers WJ. Noninvasive imaging of 
multiple myeloma using near infrared fluorescent molecular probe. Paper presented at: 
Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications 
VIII, 2016. 
 
14. Bae MH, Oh S-H, Park C-J, et al. VLA-4 and CXCR4 expression levels show contrasting 
prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia. Ann 
Hematol. 2015;94:1631-1638. 
 
15. Riaz W, Pham J, Zhang L, et al. Prognostic Significance of VLA4 and CD44 Expression 
by Flow Cytometry in Multiple Myeloma (MM). Blood. 2012;120:4975-4975. 
 
16. Soodgupta D, Hurchla MA, Jiang M, et al. Very Late Antigen-4 (α4β1 Integrin) Targeted 
PET Imaging of Multiple Myeloma. PLoS One. 2013;8:e55841. 
 
17. Bretscher MS. Circulating integrins: alpha 5 beta 1, alpha 6 beta 4 and Mac-1, but not 




18. Rainero E, Howe Jonathan D, Caswell Patrick T, et al. Ligand-Occupied Integrin 
Internalization Links Nutrient Signaling to Invasive Migration. Cell Reports. 2015;10:398-413. 
 
19. Yannaki E, Papadopoulou A, Athanasiou E, et al. The proteasome inhibitor bortezomib 






Chapter 4: Longitudinal MRI of bortezomib-treated diffuse tumor 
burden in intramedullary myeloma 
4.1 Overview 
In this study, magnetic resonance imaging (MRI) was used to perform longitudinal, 
noninvasive imaging of the bone marrow (BM) space in a diffuse infiltration model of 
intramedullary MM. MRI is well established in clinical MM care, and is used extensively in 
diagnosis, staging, and identifying therapy response. However, there is a paucity of preclinical 
MRI applications for imaging MM disease progression and therapy response. Preclinical studies 
afford significant insight into BM remodeling as a function of pathogenesis and treatment. Here, 
we have validated longitudinal, multi-parametric MRI for imaging changes in the BM following 
treatment with bortezomib, which is known to induce significant remodeling of the bone and BM 
microenvironments. To approximate diffuse infiltrative lesions, the immunocompetent 
C57Bl/KaLwRij mouse strain was implanted intravenously with the syngeneic 5TGM1-GFP 
cells. 
Our results showed that uptake of gadolinium contrast increased in the relapsed, treated 
cohort compared to the untreated, tumor-bearing animals. There were also significant regional 
differences in T1-weighted normalized signal intensities following bortezomib therapy, which 
correlated to spatially heterogeneous tumor viability. Parametric T2 relaxation identified overall 
tumor burden within the BM. Histology also indicated a reduction in total tumor burden and cell 
density following therapy, which was in line with MRI observations. This study highlighted 
potential preclinical MR markers for assessing viable tumor burden and BM permeability 
following therapy, and demonstrated the application of longitudinal, noninvasive imaging in an 
immunocompetent, intramedullary setting. The material covered in this chapter has been 
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submitted to NMR in Biomedicine, under the title, “Longitudinal preclinical magnetic resonance 
imaging of diffuse tumor burden in intramedullary myeloma following bortezomib therapy.” 
4.2 Introduction 
Multiple myeloma (MM) is a cancer of terminally differentiated plasma B-cells in the bone 
marrow (BM) that accounts for approximately 15% of all mortalities associated with hematologic 
malignancies (1,2). Despite recent improvements in MM treatment, the efficacy of MM 
therapeutic strategies is still variable, especially at the late stages of cancer progression (3). 
Changes in therapy efficacy are influenced, in part, by the interactions of myeloma cells with the 
BM microenvironment. As a result, imaging strategies to noninvasively assess changes in the 
BM microenvironment can provide valuable information for treatment stratification. 
In MM, clinical magnetic resonance imaging (MRI) is used extensively to delineate 
lesions and stage disease progression following treatment (4). Traditional biological markers, 
including bone remodeling and angiogenesis-related factors and plasma cell infiltration, are 
correlated to the presence of diffuse, variegated, and focal lesions in T1-weighted, non-contrast 
enhanced and fat-suppressed, T2-weighted MRI (5,6). In particular, T1-weighted MRI revealed 
a high correlation between diffuse infiltration and poor prognosis (5). Diffusion weighted imaging 
of MM patients has also identified significant differences in median apparent diffusion 
coefficients between responders and non-responders to systemic treatment (7). Kinetic 
modeling of vascular transport with T1-weighted, dynamic contrast-enhanced (CE) imaging 
identified increases in BM angiogenesis and vascular bed density, which may correspond to the 
transition to malignant states of MM (8). Finally, magnetic resonance spectroscopy of spinal and 
pelvic BM showed a statistically significant increase in lipid fractions in patients responding to 
therapy, indicating a reduction in the ratio of hematopoietic marrow to adipose tissue (9). These 
clinical studies demonstrate that MRI is as an attractive option for noninvasively studying 
86 
 
relative changes in the BM microenvironment during disease progression and for monitoring 
therapy response. 
While the role of MRI is well established in the clinic, studies demonstrating the potential 
of preclinical MRI in MM are scarce. Due to its excellent soft-tissue contrast and resolution, MRI 
provides a preclinical platform for studying the BM microenvironment in a noninvasive, 
longitudinal manner. Here, we demonstrate the use of multi-parametric MRI for longitudinal 
imaging of the viable tumor burden in the BM in a syngeneic immunocompetent model of 
intramedullary diffuse MM. Treatment with a proteasome inhibitor, bortezomib, was performed, 
due to its relevance in MM clinical care at all stages and its effect on BM remodeling (10). 
Effective changes in MR markers were correlated with histology for validation. 
4.3 Materials and Methods 
4.3.1 Cell culture and reagents 
5TGM1-GFP cells (5TGM1; kind gift from Dr. K. N. Weilbaecher, Washington University, 
Department of Medicine) were maintained at 106 cells/mL in Iscove’s Modified Dulbecco 
Medium supplemented with 10% v/v fetal bovine serum and 1% penicillin/streptomycin (all from 
Thermo Fisher Scientific, MA, USA). Bortezomib (Sigma Aldrich, MO, USA) doses were 
prepared prior to each therapy injection. 
4.3.2 Tumor model and bortezomib therapy 
All animal studies were conducted according to protocols approved by the Washington 
University Institutional Animal Care and Use Committee. Mice were anesthetized under 2% v/v 
isoflurane/100% O2 prior to tumor implantation. Female 4-8 week old C57Bl/KaLwRij mice were 




Figure 4.1: Study design, imaging, and therapy timeline. Untreated tumor-bearing (N = 5) 
5TGM1/KaLwRij were imaged weekly with non-CE T2 parametric mapping and 3D CE T1-
weighted MR weekly beginning two weeks post 5TGM1 tumor implantation. The bortezomib 
treatment cohort (N = 9) was similarly implanted with 5TGM1 tumors and injected with 
bortezomib via intraperitoneal injection at 1 mg/kg twice a week, beginning two weeks post 
tumor implantation. On imaging days (e.g., day 14, 21, 28), therapy and vehicle injections were 
performed immediately following imaging. As with the untreated tumor-bearing cohort, each 
mouse was imaged weekly with non-CE T2 parametric mapping and a 3D CE T1-weighted 
pulse sequence. 
Tumor-bearing mice were separated into randomly assigned untreated (n=5) and 
bortezomib-treated (n=9) independent cohorts (Figure 4.1). Bortezomib therapy was 
administered intraperitoneally at 1 mg/kg twice a week beginning on day 14 post tumor 
implantation(11). Untreated animals received the vehicle control on the same schedule. Non-
tumor bearing animals (n=4) were imaged once. 
4.3.3 Preclinical MRI 
Preclinical 1H MRI experiments were performed on a 4.7-T Agilent/Varian (Santa Clara, 
CA, USA) DirectDrive MRI scanner employing a horizontal Oxford Instruments (Abington, 
Oxfordshire, UK) magnet with 40-cm clear bore diameter and an actively shielded Resonance 
Research Inc. (Billerica, MA) gradient/shim coil assembly of 11.5-cm bore diameter driven by 
Oy International Electric Company (IEC; Helsinki, Finland) model A-240 amplifiers (~70 
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gauss/cm is achievable with a rise time of ~120 µs). All imaging experiments were conducted 
under 1% v/v isoflurane/100% O2 anesthesia. Mice were placed prone, with the hind leg 
immobilized within a tuned circular radiofrequency surface coil. The hind leg was used to image 
changes in large BM sites with minimal motion artifacts. Body temperature was maintained with 
an external air heater. Planning and localization of femur and tibia regions of interest (ROIs) 
were performed using sagittal (field of view (FOV) 2.5x2.5x0.5 cm3) and transverse (FOV 
1.5x1.5x1 cm3) T1-weighted gradient echo sequences (flip angle 20o, repetition time (TR) 
100ms, echo time (TE) 5 ms). Following field shimming, T2 parametric maps were collected 
using multi-slice, multiple spin echo (FOV 2x2x0.3 cm3, TR 2s, 7.1 ms ≤ TE ≤ 113.5 ms, 16 
echoes, 0.156x0.156x1 mm3 voxel dimensions, 128x128x3 matrix dimensions, 1 average). Mice 
were then injected intraperitoneally with 12 µmol MultiHance (Bracco Diagnostics, NJ, USA). To 
allow the contrast agent to accumulate and approach steady state, CE T1-weighted gradient 
echo 3D images were collected 8-10 minutes following injection of the agent (FOV 2x1x1 cm3, 
flip angle 20o, TR 25 ms, TE 4.2 ms, 0.78x0.78x0.78 mm3 voxel dimensions, 128x256x128 
matrix dimensions, 4 averages). 
4.3.4 Bone histology and imaging 
Following euthanasia, femur and tibia were removed and decalcified. Bone tissue was 
embedded in paraffin, sectioned at 5 µm thickness, and stained with hematoxylin and eosin 
(H&E). Brightfield images of the H&E stained slides were acquired using the NanoZoomer 
Digital Pathology System (NanoZoomer 2.0-HT, Hamamatsu, Japan). 
4.3.5 Data analysis 
Image analysis was performed using in-house routines developed on MATLAB R2014b 
(Mathworks, MA, USA). ROIs for the femur, tibia, and muscle volumes were drawn on each 
slice of T1-weighted, non-CE and CE images using ImageJ (National Institutes of Health, MD, 
USA). To minimize variability in inter-scan T1-weighted image intensity resulting from 
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unavoidable modest variability in coil placement and subject positioning, CE T1-weighted 
images were normalized by the mean voxel intensity of the muscle volume of interest (VOI). T2 
parametric maps were generated using non-linear least squares fitting of the equation 𝑆(𝑡) =
𝐴 + 𝐵 × exp(−𝑡/𝐶) for each voxel, where S(t) is the signal intensity, t is TE, A and B are scaling 
constants, and C is the voxel-specific T2. The constant, A, accounts for both the positive, non-
zero mean of Rician noise and any steady-state, non-zero transverse magnetization resulting 
from imperfect, slice-selective 180o refocusing pulses. 
The T1-weighted CE 3D images were also analyzed using texture statistics to assess 
the spatial distribution of the signal within the femur and tibia VOIs. Image histograms were 
distributed into equally sized integer bins and voxels were relabeled to the integer values of their 
respective bins. A gray-level co-occurrence matrix (GLCM) was computed on the VOI covering 
each neighboring voxel in 3D space. Texture statistics were calculated from the 3D GLCM 
(12,13). 
Bone histology images were imported into MATLAB using ImageJ and the Bio-Formats 
application interface (14). Images were first manually segmented into femur and tibia BM ROIs, 
and then into tumor and non-tumor ROIs. Tumor burden (%) was calculated for tumor-bearing 
groups as (Total ROI area – Non-tumor area)/(Total ROI area) * 100%. 
4.3.6 Statistical analysis 
Statistical analysis on histogram and texture statistics from the imaging and histology 
was performed using GraphPad Prism 7.0 (GraphPad, CA, USA). One-way analysis of variance 
(ANOVA) with Tukey multiple comparisons test was used to assess statistical significance 
between multiple treatment groups for femur and tibia VOI individually. A p-value less than 0.05 




4.4.1 Observed differences in normalized 3D CE T1-weighted MRI 
 
Figure 4.2: Representative sagittal sections of T1-weighted CE-MRI. Each voxel in the volume 
was normalized by the mean of representative muscle VOI located in the lower leg. (A) Non-
tumor bearing. (B) Untreated tumor-bearing, week 4. (C) Treated tumor-bearing, week 6. Red 
arrows highlight regions of significant spatial intensity variation. Scale bar, 4 mm. 
Diffuse tumor burden in the femur and tibia VOIs in treated and untreated 
C57Bl/KaLwRij mice bearing intramedullary 5TGM1 tumors was visualized using normalized CE 
T1-weighted imaging. Due to heterogeneity in the BM composition of the femur and tibia, end-
stage untreated mice displayed spatial variation in T1-weighted CE image intensity in the femur, 
and to a lesser extent, tibia (Figure 4.2B). By contrast, non-tumor bearing (Figure 4.2A) and 
end-stage treated (Figure 4.2C) groups showed minimal spatial heterogeneity in either femur or 
tibia. These observations were supported by the equivalent gray-level normalized images, which 
corroborated the overall homogeneity of the signal in the non-tumor and treated mice (Figure 
4.3A, C) relative to the untreated animals (Figure 4.3B). Mid-stage, untreated (week 3) and 
treated (week 4) mice had similar spatial distributions in both femur and tibia (Figure 4.4A-D). 
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Textural analysis of these images using 3D GLCM and Haralick features confirmed the 
observed spatial distributions. The GLCM autocorrelation, which measures the fineness of the 
textured image, was significantly reduced in the femurs of untreated tumor-bearing mice 
(p<0.05) relative to the non-tumor bearing and treated tumor-bearing groups (Figure 4.5A). 
Furthermore, there was a statistically significant increase in the difference in autocorrelation 
between the treatment time points and the pre-treatment baseline relative to the untreated 
groups (p<0.01) ((Figure 4.5B). These results demonstrate that region-specific permeability and 
contrast agent uptake via vascular availability are affected by bortezomib treatment response. 
 
Figure 4.3: Gray-level, normalized, CE T1-weighted representative sagittal sections. Images 
were normalized by distributing the grayscale intensity value of each voxel into 8 equal-width 
bins. (A) Non-tumor bearing. (B) Untreated tumor-bearing, week 4. (C) Treated tumor-bearing, 




Figure 4.4: Representative sagittal sections of T1-weighted CE and T2 parametric images of 
mid-series time points in untreated and treated tumor-bearing mice. (A-B) T1-weighted CE 3D 
MRI, normalized by the mean voxel intensity of the representative muscle ROI in untreated 
(week 3) and treated (week 4) tumor-bearing. (C-D) T1-weighted CE 3D MRI, normalized by 
gray level equalization. (E-F) T2 parametric maps of femur and tibia ROIs overlaid on T1-
weighted non-CE oblique slices. Scale bar, 4 mm; T2 range, 0-60 ms. 
Statistical analysis of mean T1-weighted CE normalized intensities supported the spatial 
heterogeneity observations in representative sections (Figure 4.6A). End-stage (weeks 5-6), 
treated tumor-bearing mice showed a statistically significant increase in T1-weighted intensity 
relative to the mid-stage (weeks 3-4) treated and untreated groups in the tibia (p<0.01). 
Interestingly, in the femur, the mean T1-weighted intensity in the non-tumor bearing group was 
significantly higher (p<0.001) than in the rest of the groups and had a tighter intra-group 
distribution relative to the non-tumor tibia VOI. To minimize the underlying intra-animal 
heterogeneity, the %difference between the pre-treatment and the latter stage time-points was 
calculated. The end-stage treated group showed a statistically significant increase in the 
%difference in T1-weighted intensity relative to the mid-stage treated and untreated groups in 




Figure 4.5: Mean autocorrelation of 3D gray-level co-occurrence matrix (GLCM) in tibia and 
femur VOIs in T1-weighted CE images. (A) Mean GLCM autocorrelation for non-tumor bearing 
(NT), untreated tumor-bearing at weeks 3 (U3) and 4 (U4), and treated tumor-bearing at weeks 
3-4 (MT) and weeks 5-6 (ET) groups. (B) Mean GLCM autocorrelation relative to week 2 
baseline for each animal (%difference = (Time-point Mean – Baseline Mean)/(Baseline Mean)). 
Statistical significance was assessed using a one-way ANOVA with Tukey multiple comparisons 
test performed individually on the tibia and femur VOIs (*p < 0.05). Whiskers indicate 5-95% 
confidence intervals. 
 
Figure 4.6: Mean CE T1-weighted intensity, normalized by mean muscle intensity, in femur and 
tibia VOIs. (A) Mean CE T1-weighted normalized intensity in non-tumor bearing (NT) mice, 
untreated tumor bearing mice at weeks 3 (U3) and 4 (U4), and treated tumor-bearing mice at 
weeks 3-4 (MT) and 5-6 (ET). (B) Mean CE, T1-weighted normalized intensity relative to week 2 
baseline for each animal (%difference = (Time-point Mean – Baseline Mean)/(Baseline Mean)). 
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Statistical significance was calculated using a one-way ANOVA with the Tukey multiple 
comparisons test performed individually on the tibia and femur VOIs (*p < 0.05, **p < 0.01, ***p 
< 0.001; closed line indicates comparison between two groups, open-ended line indicates 
statistical significance between one group against all other included groups). Whiskers indicate 
5-95% confidence intervals. 
4.4.2 Effect of disease stage and bortezomib therapy on T2 parametric maps 
 
Figure 4.7: Representative T2 parametric maps of femur and tibia BM. (A) Non-tumor bearing 
mice. (B) Untreated tumor-bearing mice, week 4. (C) Treated tumor-bearing mice, week 6. 
Femur and tibia T2 maps were overlaid on non-CE, oblique, T1-weighted intensity images 
normalized by the mean voxel intensity of the muscle ROI. Scale bar, 4 mm; T2 range 0-60 ms. 
To identify the effect of treatment on viable tumor burden, T2 parametric maps were 
generated. These maps identified substantive changes in the tibia VOI after tumor implantation. 
The non-tumor-bearing tibia had low overall T2 (Figure 4.7A), relative to all other groups. By 
contrast, representative end-stage untreated (week 4) and treated (week 6) groups displayed 
similar overall distribution of T2 values in both VOIs. There was an increase in spatial 
heterogeneity in the treated tibia VOI relative to the femur VOI and both VOIs in the 
representative untreated image (Figure 4.7B, C). Interestingly, high T2 values (>45 ms) in both 
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groups were clustered near the epiphyseal plate of the femur and tibia. This result was seen in 
the mid-stage untreated (week 3) and treated (week 4) representative images as well, albeit to a 
lesser degree (Figure 4.4E, F). The representative T2 parametric maps correlated with changes 
in the viable tumor burden and changes in the homogeneity of the BM tissue observed in the 
representative T1-weighted CE images. 
 
Figure 4.8: Mean T2 in femur and tibia VOIs. (A) Mean T2 in non-tumor bearing (NT) mice, 
untreated tumor-bearing mice at weeks 3 (U3) and 4 (U4), and treated tumor-bearing mice at 
weeks 3-4 (MT) and weeks 5-6 (ET). (B) Mean T2 relative to week 2 baseline for each animal 
(%difference = (Time-point Mean – Baseline Mean)/(Baseline Mean)). Statistical significance 
was assessed using a one-way ANOVA with Tukey multiple comparisons test performed 
individually on the tibia and femur VOIs (*p < 0.05, **p < 0.01, ***p < 0.001; closed line indicates 
comparison between two groups, open-ended line indicates statistical significance between one 
group against all other included groups). Whiskers indicate 5-95% confidence intervals. 
Quantitative analysis of the T2 parametric images showed similar overall trends to the 
qualitative observations from the representative parametric images (Figure 4.8A). In both femur 
and tibia, mean T2 times in the end-stage (weeks 5-6), treated tumor-bearing group was 
significantly increased relative to the T2 times in the mid-stage treated group (p<0.01). The T2 
relaxation time in the end-stage, treated group showed a statistically significant increase relative 
to the end-stage untreated group in the tibia (p<0.05), but not femur. In both VOIs, the non-
tumor bearing group had low mean T2, although as observed, the non-tumor T2 in the tibia was 
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significantly lower than in the other groups (p<0.001). Following normalization with pre-
treatment imaging, the treated end-stage and mid-stage groups were more heterogeneous in 
the tibia VOI than in the femur (Figure 4.8B). In the tibia, there was a statistically significant 
difference in the %T2 difference between the untreated groups and the end-stage treated group 
(p<0.01). By contrast, in the femur, there was a significant reduction in the %T2 difference mid-
stage treated relative to the end-stage untreated and treated groups (p<0.05). These results 
suggest that the T2 parametric maps are responsive to the overall disease stage following 
treatment. 
The spatial and temporal distributions of contrast uptake and T2 relaxation times in the 
BM were most affected by response to bortezomib therapy. Spatial intensity heterogeneity was 
maximized in the untreated tumor-bearing group and reduced following treatment with 
bortezomib. Similarly, mean T2 relaxation times were significantly increased following tumor 
implantation and showed significant difference from the untreated groups relative to pre-
treatment imaging. In summary, T1-weighted CE imaging and T2 parametric maps were 
indicative of viable tumor burden, with significant longitudinal changes seen at the end-stage of 
the treated tumor-bearing group. 
4.4.3 Validation of imaging results with H&E of femur and tibia BM 
To validate MRI results, the femur and tibia were extracted at end-stage disease and 
stained with H&E. The %tumor burden was quantified as the total tumor tissue relative to non-
tumor tissue in the femur and tibia ROIs. Non-tumor bearing mice had high lipid content 
clustered near the femur epiphyseal plate and low overall cell density (Figure 4.9A). In the end-
stage, untreated tumor-bearing group, the healthy BM was overtaken by densely packed, 
mononuclear tumor cells (Figure 4.9B, Figure 4.10B). Non-tumor BM tissue was sequestered 
in the epiphysis of the femur and tibia. By contrast, the end-stage, treated tumor-bearing group 
showed a statistically significant reduction in tumor burden in the femur (p<0.001) and tibia 
(p<0.001) relative to the untreated mice (Figure 4.9C, Figure 4.10B). Tumor tissue was 
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primarily concentrated proximal to the epiphyseal plate in both femur and tibia, with minimal 
tumor burden at distal sites in either bone (Figure 4.9C). Tumor burden was also highest near 
the epiphyseal plate in the mid-treatment cohort, although the overall distribution of tumor 
burden within the cohort was highly heterogeneous in both femur and tibia (Figure 4.10A, B). 
These results suggest that bortezomib therapy restricts tumor cell growth to the rapidly growing 
epiphyseal plate region, which may correlate with the observed high T2 values near the 
epiphyseal plate in the end-stage treated group (Figure 4.8C). 
 
Figure 4.9: Representative H&E sections. (A) Non-tumor bearing mice. (B) Untreated tumor-
bearing mice, week 4. (C) Treated tumor-bearing mice, week 6. Green outline indicates tumor 
boundaries. Top inset highlights non-tumor cells, as indicated by the presence of 
megakaryocytes (red arrowhead) and segmented nuclei (red arrow). The bottom inset highlights 
tumor cells, as indicated by the presence of mitoses (green arrowhead) and oval plasma cell 




Figure 4.10: Representative H&E sections and quantification of total tumor burden. (A) Mid-
treatment, week 4. Green outline indicates tumor boundaries. Top inset highlights non-tumor 
cells, as indicated by the presence of segmented nuclei (red arrows). Bottom inset highlights 
tumor cells, as indicated by the presence of mitoses (green arrowheads) and oval plasma cell 
nuclei (green arrows). (B) %Tumor burden in untreated week 4 (U4) and treated weeks 3-4 (MT) 
and weeks 5-6 (ET) (%tumor burden = (Total Tissue Area – Non-tumor Area)/(Total Tissue 
Area)*100%). Statistical significance was assessed using one-way ANOVA with Tukey multiple 
comparisons test on the tibia and femur individually (***p<0.001). Whiskers denote 5-95% 
confidence intervals. Scale bar, 500 µm; Inset scale bar, 20 µm. 
In summary, histology and ex vivo tumor burden quantification demonstrated the 
difference in the distribution of tumor between the end-stage untreated and treated tumor-
bearing groups. BM in the femur and tibia of untreated animals was dominated completely by 
tumor tissue, while tumor burden was concentrated proximal to the epiphyseal plate in the 
treated animals. Tumor cell density was also reduced in both tibia and femur, especially at the 
end-stage, following relapse from bortezomib therapy. Spatial distributions of the tumor and 
normal BM in the tibia and femur were similar to the observed trends in the imaging acquired 




This study marks one of the first instances utilizing multi-parametric MRI to longitudinally 
follow changes in the BM in response to MM stage and therapy in a preclinical 
immunocompetent model. Previously, Fryer et al demonstrated that a combination of in vivo 
bioluminescence and T2-weighted tumor volume were correlated to therapy response in an 
intratibial immunocompromised model of MM (15). Similarly, Gauvain et al used a metastatic 
melanoma model in immunocompetent C57Bl/6 mice to identify early stage bone metastases 
using a combination of T2-weighted and T2 parametric imaging (16). In both studies, the tumor 
model resulted in focal lesions, which have well-defined boundaries. However, in this study, a 
diffuse intramedullary tumor model was generated by intravenous injection of syngeneic tumor 
cells within an immunocompetent strain. The advantages of this model include the preservation 
of the immune response to the myeloma cells and the presence of therapy-induced 
inflammation. Since MRI offers high soft-tissue contrast and spatial resolution, we hypothesized 
that MRI could provide a noninvasive, longitudinal approach for studying changes in the BM 
induced by bortezomib therapy and MM disease progression. The key MR features and their 
corresponding biological correlates in the BM are summarized in Table 4.1. 
Table 4.1: Summary of MR markers and their corresponding biological features for each 
imaging group relative to the untreated week 4 group. 0, no effect; +, difference in features; ++, 
significant difference in features. 



















burden N/A 0 0 ++ ++ 
Mean T2 relaxation 
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burden N/A 0 0 + ++ 
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T1-weighted, CE, 3D MRI signal intensities were indicative of contrast uptake within 
regions of tissue. Gadolinium-based contrast agents induce shortening of T1 relaxation times, 
resulting in increases in T1-weighted signal intensity in highly vascular and permeable regions 
relative to necrotic and less vascularized regions (17). The uptake of contrast within the BM in 
the femur and tibia was spatially heterogeneous, especially in the end-stage, untreated, tumor-
bearing animals. In general, significant spatial heterogeneity and the presence of well-defined 
regions of differential contrast uptake within the BM were restricted to the femur in the untreated 
mice. This could be due to the presence of higher overall hematopoiesis in the femur, with 
concentrated marrow adipocyte tissue near the epiphyseal plate in the femur. The role of 
adipose tissue in myeloma progression is considered controversial, with some literature 
presenting a supporting role for adipose tissue and other studies showing that adipose tissue 
may restrict myeloma growth (18). Nevertheless, the presence of adipose tissue in the BM may 
result in increased myeloma cell viability, thus generating the region-specific uptake patterns 
seen in the T1-weighted CE MRI. The underlying hematopoietic niches may also drive the 
concentrations of vascularized and accessible tumor burden within the femur BM, especially in 
sites distal to the femur epiphyseal plate. 
Treatment with bortezomib also induced increases in contrast agent uptake within the 
BM in both femur and tibia. Bortezomib causes significant marrow remodeling, resulting in 
reduction in osteoclast activity and cytokine secretion, and inhibition of tumor-induced 
angiogenesis (19,20). At the same time, healing and tumor cell death induced by bortezomib 
may also generate increases in angiogenesis and inflammation, which may result in increased 
uptake of contrast within high tumor burden regions after relapse. By contrast, in the mid-stage 
treated group, bortezomib efficacy and inhibition of neo-vascularization likely dominates, 
resulting in low normalized T1-weighted intensity.  
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In contrast to T1-weighted CE imaging, which was directly correlated to tumor 
vascularization and permeability, T2 parametric maps are representative of tumor burden and 
overall water content. There was less spatial heterogeneity in the T2 parametric maps, although 
this observation may have partially resulted from the reduced resolution in the T2 maps 
compared to the T1-weighted 3D images. T2 values were highest in both treated and untreated 
mice near the epiphyseal plate. This may be caused by the high tumor burden in those regions 
due to the presence of hematopoietic niches in the epiphysis and the availability of tumor-
promoting cellular and extracellular matrix factors. Interestingly, mean T2 relaxation time was 
significantly increased in the tibia of the tumor-bearing groups relative to the non-tumor bearing 
group. The increase in T2 relaxation from the non-tumor group compared to the tumor-bearing 
groups was not as exaggerated in the femur. These trends may be a function of the underlying 
composition of the femur and tibia in the C57Bl/KaLwRij model. There is higher hematopoietic 
and cellular content in the femur BM, with the tibial BM, especially in the distal tibia, dominated 
by adipose tissue (21). In the presence of myeloma, T2 relaxation times increased, although 
interestingly, the relative difference in T2 relaxation was higher in the treated animals than in the 
untreated groups. These results suggest that T2 relaxation is indicative of overall tumor burden 
and post-treatment disease progression.  
Histology with H&E staining was used to validate the MRI observations. Tumor burden in 
the end-stage untreated animals completely displaced normal BM in the femur and tibia. This 
result approximates advanced MM in humans, with homogeneous, packed diffuse infiltration 
dominating the BM (22). The lack of marrow adipose tissue in the tumor-bearing animals may 
be partly due to the age of the mice, since significant changes in marrow adipocyte depositions 
occur in older animals. The study used young, 4-6 week old mice, since young animals have 
high rates of bone remodeling and higher plasticity in the marrow composition. Both mid-
treatment and relapsed end-stage cohorts had reduced tumor burden, which was concentrated 
proximal to the epiphyseal plate. However, cells in the BM of the mid-treatment group were 
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more densely packed compared to the relapsed group, and were qualitatively similar in density 
to the end-stage untreated cohort. The observed continuum of cell densities in the treated and 
untreated groups, and the highly heterogeneous tumor burden in the mid-treatment group, is 
likely caused by the individual kinetics and response rates to bortezomib therapy. The 
concentration of the tumor tissue at the epiphyseal plate also agreed with the observed 
increases in normalized T1-weighted intensity and T2 relaxation times at the epiphyseal plate. 
The tumor cells were also less densely packed in the treated mice relative to the highly packed 
tumor tissue in the untreated BM, which likely resulted in improved viability. It is likely that the 
improvement in tumor viability resulted in the relatively large difference in T2 relaxation time 
following therapy. 
The main limitations of this study are the absence of validation with a focal lesion model 
a non-tumor bearing, treated control cohort. Contrast uptake and changes in the spatial 
distribution of signal intensities were affected by the underlying heterogeneity in the distribution 
of hematopoietic and fatty marrow in the BM. Comparison with a well-circumscribed, focal lesion 
model may further validate the observations of this study and minimize the effect of 
spatiotemporal heterogeneity on the imaging results, especially at early and mid-stage disease. 
Finally, T2 relaxation times and normalized T1-weighted intensities in the both tumor-bearing 
groups were compared to the non-tumor bearing, untreated cohort. Since mean T2 relaxation 
times were significantly increased from the non-tumor group to the tumor bearing groups, an 
additional cohort with non-tumor bearing, bortezomib-treated animals may provide a useful 
control for therapy-induced inflammation. 
4.6 Conclusion 
In conclusion, this study demonstrates that T1-weighted CE MRI and T2 relaxation times 
are indicative of disease progression and response to bortezomib therapy in an 
immunocompetent intramedullary model of MM. As such, it marks the first instance of using MRI 
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to longitudinally study the behavior of the BM in the preclinical model with diffuse MM infiltration, 
showing significant histogram and textural feature correlation to viable tumor burden in the 
presence of myeloma therapy. The study also highlighted potential preclinical MRI markers for 
assessing changes to the BM induced by MM and therapy. Future studies will include MR 
spectroscopy to assess changes in adipose tissue composition in response to myeloma in both 
young and old mice, the use of alternate hypo-proliferative myeloma cell lines, and testing with 
combination therapies and newer proteasome inhibitors. 
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Chapter 5: Conclusions and Future Work 
5.1 Summary 
This thesis aimed to identify preclinical imaging markers correlating to therapy response 
in MM for efficient imaging, with the long term goal of improving staging and patient 
stratification. To achieve this goal, the project was designed to address myeloma pathogenesis 
and therapy efficacy through a micro-environmental lens at different levels of granularity. Thus, 
these studies followed myeloma progression and response to clinically relevant therapies 
through three specific aims: 
Aim 1: To validate LAT1 surface expression imaging using FDOPA-PET and develop FDOPA-
PET uptake metrics as a surrogate for melphalan efficacy 
In this study, I adapted the phenylalanine analog 18F-FDOPA for imaging melphalan 
therapy response in extramedullary myeloma. The uptake of melphalan and 18F-FDOPA is 
mediated by LAT1, which is overexpressed in several cancers and is linked to poor prognosis in 
MM. 18F-FDOPA uptake was significantly reduced in melphalan-treated mice, as was uptake of 
the gold standard 18F-FDG. These results demonstrated that 18F-FDOPA-PET provides 
complementary imaging of LAT1 behavior in MM to currently established 18F-FDG-PET. 
The conclusions regarding 18F-FDOPA and 18F-FDG were validated using 
immunohistochemistry of the tumor and muscle tissue using antibodies against LAT1, GLUT1, 
and CD31. GLUT1 and CD31 are markers for glucose uptake and vascularity, respectively. 
LAT1 expression in melphalan-treated tumors was heterogeneous, and was increased relative 
to vehicle-treated tumors in some animals, while GLUT1 expression remained qualitatively 
similar between the treated and untreated cohorts. This heterogeneity in LAT1 expression is 
likely driven by an increase in tissue vascularity, as visualized by anti-CD31 staining, and 
reduction in structural tumor volume. These results highlight the importance of LAT1 for 
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myeloma cell function, and imply the presence of other sources of resistance to offset the 
melphalan-induced downregulation of LAT1 expression. 
Aim 2: To study the uptake of the VLA-4 specific optical contrast agent for identifying VLA-4 
expression in vivo and in response to bortezomib therapy 
In this aim, I comprehensively validated the peptidomimetic near-infrared fluorophore 
LLP2A-PEG4-Cy5 (LLP2A-Cy5) for economical and high-throughput imaging of activated VLA-4 
expression. The Shokeen research group has extensively published on the use of the nuclear 
LLP2A analog for imaging activated VLA-4 expression in intramedullary myeloma pathogenesis. 
Furthermore, we have shown cell line and patient-specific heterogeneity in VLA-4 expression 
using the fluorescent LLP2A-Cy5. Here, we were interested in imaging VLA-4 expression 
following bortezomib therapy, since bortezomib induces downregulation of VLA-4 and causes 
partial inhibition of cell adhesion-mediated drug resistance. Imaging was performed in 
intramedullary, diffuse lesions, within an immunocompetent MM model to accurately study 
effects of the immune system on MM pathogenesis. 
The results of this aim proved the sensitivity and specificity of LLP2A-Cy5 relative to the 
more established nuclear LLP2A conjugate. In vitro studies showed nanomolar specificity of 
LLP2A-Cy5 to activated VLA-4 expression, while confocal imaging established the 
predominantly cell surface concentration of LLP2A-Cy5 binding. Ex vivo analysis of LLP2A-Cy5 
uptake demonstrated the viability of using activated VLA-4 expression for studying the effects of 
proteasome inhibitor therapy in MM. 
Aim 3: To identify preclinical MRI parameters for longitudinal imaging of diffuse, intramedullary 
tumor burden in response to myeloma therapy 
Finally, in aim 3, I addressed the gross, anatomical scale changes in the BM induced by 
both MM disease progression and response to bortezomib therapy. Bortezomib induces BM 
remodeling in addition to abrogating adhesion-mediated drug assistance. To assess BM 
remodeling in a longitudinal manner in a diffuse infiltrative intramedullary MM model, I evaluated 
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preclinical, high-resolution MRI parameters. While MRI is used extensively in MM clinical care, 
there is a scarcity of preclinical MRI studies for noninvasive, longitudinal imaging of MM 
pathogenesis. In this study, MR T1-weighted and T2 parametric markers were correlated to 
structural changes in the BM following bortezomib therapy. 
The MR imaging results were validated with histology of the femur and tibia BM at each 
treatment stage. H&E staining of the BM was used to assess tumor burden. In untreated 
animals, end-stage disease caused near-complete infiltration of the BM space by myeloma 
cells, while in end-stage, treated disease, the tumor was primarily concentrated near the 
epiphyseal plate in the distal femur and proximal tibia. These observations correlated to T1-
weighted contrast uptake and parametric T2 using both summary statistics and spatial analysis. 
Crucially, high-resolution imaging established the spatial heterogeneity between BM sites. 
5.2 Limitations 
There are certain limitations to our approach in this project. Most aim-specific limitations 
are addressed in each chapter individually, but there were some inherent, general limitations 
that may affect the results in the project. The primary limitations were the use of a single 
myeloma cell line and sample sizes in some of the experiments. Both limitations are easily 
addressed by additional validation studies. 
Additionally, in aim 1, the use of the 5TGM1-GFP cell line presented translatability 
challenges, due to two main factors. The cell line is highly proliferative, resulting in rapidly 
growing tumors, which do not necessarily represent the general MM progression, where the 
medullar spaces motivate quiescence and slow growth. As a result of this growth behavior, 
5TGM1 cells are also highly glucose avid, which increases 18F-FDG intratumoral uptake. In the 
general MM population, the overexpression of GLUT1 and hexokinase is inconsistent, resulting 
in poor 18F-FDG sensitivity in intramedullary disease. These concerns were slightly abrogated 
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due to the use of a late-stage, extramedullary model, although it may be necessary to study 
intramedullary models to establish 18F-FDOPA-PET for use in MM care. 
In aims 1 and 2, single time point imaging was used, at the end-stage of the treated and 
untreated groups. This was done to reduce complexity inherent in longitudinal imaging. 
However, due to clonal and spatiotemporal heterogeneity in intra- and inter- patient levels, the 
comparison of these two groups may lose relevant information regarding changes in expression 
resulting from disease progression. Use of longitudinal imaging would be especially helpful for 
aim 2, where end-point imaging of the LLP2A-Cy5 contrast reduces the value of fluorescent 
imaging. 
In aim 3, the intra-site heterogeneity was hinted at, but not fully studied. Imaging of the 
femur and tibia BM showed regional differences in viable tumor burden and BM recovery 
following bortezomib therapy. In clinical MM care, MRI of the spinal column and vertebrae is 
combined with the leg bone imaging. Furthermore, in patients, the distal BM is primarily 
composed of adipose marrow, with hematopoietic marrow concentrated in spinal and pelvic 
sites. Our model did not approximate this behavior, since we used young, 6-8 week old mice. 
These mice were used due to their rapid bone turnover and corresponding BM activity, which 
exaggerated the myeloma-induced changes in the BM for MR validation. 
Finally, we used single agent therapies for each of our aims to simplify the experimental 
models and validate the imaging strategies. Single agent treatment is not used in clinical care to 
delay the onset of resistance to the individual agents. Future studies should address this 
limitation by using clinically relevant combinations to study the effect on the targeted imaging 




5.3 Future work 
As with the limitations, aim-specific future studies were addressed in each chapter. Here, 
briefly, there are some general future studies that could be performed to improve upon the 
results and conclusions generated by each aim. 
One important addition to the intramedullary model would be to test intramedullary 
imaging on focal lesions, since MM patients typically have a combination of diffuse and focal BM 
lesions. Such a model would be generated using direct injection of cells into the tibia. Crucially, 
this approach also generates metastatic tumor burden at late stages of the disease, and may 
also show diffuse infiltration in the spinal column. Use of multiple cell lines can also approximate 
different MM pathogenic behaviors for assessing the robustness of each biomarker in the 
presence of heterogeneous protein expression and growth profiles. 
This thesis highlighted use of longitudinal imaging for identifying changes in the BM 
microenvironment in response to disease progression and treatment response. The use of the 
5TGM1 cell line also allowed the influence of the intact immune system on the myeloma 
pathogenesis, although due to the rapid proliferation profile in vitro and in vivo, disease 
progression within the BM was accelerated. In addition, the cell line presented an external 
stressor, which may have adversely affected the biology, resulting in potentially inaccurate 
conclusions drawn from the imaging data. As a result, one exciting strategy for studying 
changes in biomarker expression and BM remodeling is to use naturally progressing MM model 
with the vk*myc animal model. Longitudinal imaging in this model would help identify novel 
features that could be directly translated for clinical care. 
Finally, there is growing availability of tandem PET and MRI systems (PET/MRI) that aim 
to utilize the functional imaging and high-resolution, soft tissue contrast of the constituting 
technologies. Our work has highlighted the use of each technology in assessing changes to 
expression of critical surface markers and the overall BM structure. Therefore, there is potential 
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for using PET/MRI to generate co-registered results that can be used for early stratification of 
therapy response. 
5.4 Conclusions 
In conclusion, this study used a combination of qualitative observations and quantitative 
metrics for addressing therapy response monitoring and stratification in MM. We took an 
integrated, multi-modal approach to assessing therapy response by observing changes to a 
spectrum of myeloma pathogenic behaviors. This structured approach harnessed the unique 
role of the BM microenvironment in supporting MM progression and response to clinical relevant 
therapies. In doing so, we have validated the use of several imaging markers in preclinical MM 
models that have translation potential. 
